Document:

Collaboration Agreement, dated October 8, 2010

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 Exhibit 10.77 
 COLLABORATION AGREEMENT 

THIS COLLABORATION AGREEMENT (the “Agreement”) is made and entered
into as of October 8, 2010 (the “Effective Date”) by and between EXELIXIS, INC., a Delaware corporation having its principal place of business at 170 Harbor Way, P.O. Box 511, South San
Francisco, California 94083-0511 (“Exelixis”), and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York, 10154
(“BMS”). Exelixis and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 
 RECITALS 
 A. BMS is a multinational health care company that has
expertise and capability in researching, developing and marketing human pharmaceuticals. 
 B. Exelixis is a drug discovery company that
has expertise and proprietary technology relating to compounds that modulate the target known as ROR. 
 C. BMS and Exelixis desire to
establish a collaboration to apply such Exelixis technology and expertise to the discovery, lead optimization and characterization of Small Molecule Compounds, and to provide for the development and commercialization of novel therapeutic and
prophylactic products based on such compounds. 
 NOW, THEREFORE, the Parties agree as follows: 

 

	1.	DEFINITIONS 

 Capitalized terms used in
this Agreement (other than the headings of the Sections or Articles) have the following meanings set forth in this Article 1, or, if not listed in this Article 1, the meanings as designated in the text of this Agreement.

 1.1 “Affiliate” means, with respect to a particular Party, a person, corporation, partnership,
or other entity that controls, is controlled by or is under common control with such Party. For the purposes of the definition in this Section 1.1, the word “control” (including, with
correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one (1) or more intermediaries, to
direct or cause the direction of the management and policies of such entity, whether by the ownership of at least fifty percent (50%) of the voting stock of such entity, by contract or otherwise. 

1.2 “ANDA” means an Abbreviated New Drug Application submitted to the FDA in conformance with applicable laws and
regulations, or the foreign equivalent of any such application in any other country. 
 1.3 “BMS Licensed
Know-How” means all Information (other than Patents) Controlled by BMS and its Affiliates, including Information Controlled jointly with Exelixis, as of the 

 
Effective Date or during the term of the Agreement that: (a) relates to a Licensed Compound, a composition containing a Licensed Compound, a formulation containing a Licensed Compound, or
the manufacture or use of a Licensed Compound; and (b) is [ * ] for Exelixis to exercise the rights licensed to it under the Agreement or to perform its obligations under the Agreement. 

1.4 “BMS Licensed Patents” means all Patents Controlled by BMS and its Affiliates, including Patents Controlled jointly
with Exelixis, as of the Effective Date or during the term of this Agreement that: (a) cover a Licensed Compound, a composition containing a Licensed Compound, a formulation containing a Licensed Compound, or the manufacture or use of a
Licensed Compound; and (b) are [ * ] for Exelixis to exercise the rights licensed to it under the Agreement or to perform its obligations under the Agreement. 
 1.5 “BMS ROR Compound” means: (a) any Small Molecule Compound that is an ROR Antagonist and is Controlled by BMS and/or its Affiliates as of the Effective Date or during the Term,
wherein such compound (i) (1) [ * ] or [ * ] and/or [ * ] an ROR Antagonist [ * ] the [ * ] or (2) is [ * ] and [ * ] an ROR Antagonist (A) [ * ] or [ * ] and/or [ * ] in the [ * ] the [ * ] or (B) [ * ] or [ * ] and/or [ *
] in the [ * ] the [ * ], and (ii) is [ * ], a [ * ], or a [ * ] or [ * ]; or (b) any [ * ], or [ * ] of [ * ]. Those ROR Antagonists that are [ * ] Controlled by BMS and/or its Affiliates as of the Effective Date are set forth in the
Disclosure Letter dated as of even date herewith. 
 1.6 “Change of Control” means any transaction in
which a Party: (a) sells, conveys or otherwise disposes of all or substantially all of its property or business; or (b)(i) merges, consolidates with, or is acquired by any other Person (other than a wholly-owned subsidiary of such Party); or
(ii) effects any other transaction or series of transactions; in each case of clause (i) or (ii), such that the stockholders of such Party immediately prior thereto, in the aggregate, no longer own, directly or indirectly, beneficially or
legally, at least fifty percent (50%) of the outstanding voting securities or capital stock of the surviving Person following the closing of such merger, consolidation, other transaction or series of transactions. As used in this
Section 1.6, “Person” means any corporation, firm, partnership or other legal entity or individual person.  
 1.7 “Collaboration” means all the activities performed by or on behalf of either Exelixis or BMS in the course of performing work contemplated in Article 3, 4 or 5.

 1.8 “Collaborative Research Period” means the period described in Section 3.2. 

1.9 “Commercialize” means to promote, market, distribute, sell (and offer for sale or contract to sell) or provide
product support for a Product, including by way of example: (a) detailing and other promotional activities in support of a Product; (b) advertising and public relations in support of a Product, including market research, development and
distribution of selling, advertising and promotional materials, field literature, direct-to-consumer advertising campaigns, media/journal advertising, and exhibiting at seminars and conventions; (c) developing reimbursement programs and
information and data specifically intended for national accounts, managed care organizations, governmental agencies (e.g., federal, state and local), and other group purchasing organizations, including pull-through activities; (d) co-promotion
activities not included in the above; (e) conducting Medical Education Activities and journal advertising; and (f) [ * ]. For clarity, “Commercializing” and “Commercialization” have a correlative meaning.

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2 

 1.10 “Controlled” means, with respect to any compound, material,
Information or intellectual property right, that the Party owns or has a license to such compound, material, Information or intellectual property right and has the ability to grant to the other Party access, a license or a sublicense (as applicable)
to such compound, material, Information or intellectual property right as provided for herein without violating the terms of any agreement or other arrangements with any Third Party existing at the time such Party would be first required hereunder
to grant the other Party such access, license or sublicense. 
 1.11 “Decision Point [ * ]” or “[ *
]” means the point at which [ * ] decides whether to [ * ] a [ * ] to [ * ] to [ * ], including [ * ] of [ * ] or [ * ] and the [ * ] of [ * ] and [ * ] of [ * ] ([ * ], etc.) to that effort. At [ * ], the following [ * ]: (a) [ * ] or
[ * ] with [ * ] and [ * ] (through [ * ]); (b) [ * ] to [ * ]; (c) [ * ] or [ * ]; (d) [ * ] in [ * ]; (e) [ * ] for the [ * ] through [ * ] and [ * ]; (f) [ * ] for [ * ] for [ * ]; and (g) [ * ]. 

1.12 “Derivative” means, for a particular ROR Antagonist, each ROR Antagonist that is [ * ] or [ * ] or [ * ] that are [
* ] of such ROR Antagonist. 
 1.13 “Development” means, with respect to a Product, those activities, including
clinical trials, supporting manufacturing activities and related regulatory activities, that are [ * ] to: (a) obtain the approval by the applicable Regulatory Authorities of the Drug Approval Application with respect to such Product in the
applicable regulatory jurisdiction, whether alone or for use together, or in combination, with another active agent or pharmaceutical product; or (b) maintain such approvals. To avoid confusion, Development [ * ]. For clarity,
“Develop” and “Developing” have a correlative meaning. 
 1.14 “Diligent
Efforts” means the carrying out of obligations or tasks in a sustained manner consistent with the commercially reasonable efforts a Party devotes to a product or a research, development or marketing project of similar market potential,
profit potential or strategic value resulting from its own research efforts. Diligent Efforts requires that the Party: (a) [ * ], (b) [ * ], and (c) [ * ] with respect to such [ * ]. 

1.15 “Disclosure Letter” means one or more mutually agreed written letters or memoranda that are delivered by each of
Exelixis and BMS to the other contemporaneously with or subsequent to the execution of this Agreement and are identified therein as a Disclosure Letter contemplated by this Agreement and any amendments or replacement thereof approved in writing by
both Parties. 
 1.16 “Dollars” or “$” means the legal tender of the United States.

 1.17 “Drug Approval Application” or “DAA” means: (a) in the United States, an NDA (or
a supplemental NDA for following indications), and (b) in any other country or regulatory jurisdiction, an equivalent application for regulatory approval required before commercial sale or use of a Product (or with respect to a subsequent
indication) in such country or regulatory jurisdiction. 
 1.18 “[ * ]” or “[ * ]” means the
point at which [ * ] decides whether to [ * ] a [ * ] to [ * ] to [ * ]. This decision point is known [ * ] as “Decision Point [ * ]” or “[ * ]”. This decision point

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 3 

 
is typically made [ * ] to [ * ] prior to the [ * ] of the [ * ] for such [ * ]. For such a [ * ], the relevant [ * ] for such [ * ] shall [ * ] include: (a) [ * ] of [ * ] in [ * ];
(b) [ * ] that [ * ] and is [ * ] to be [ * ]; (c) [ * ] that [ * ] includes [ * ] and [ * ] and [ * ] to [ * ], [ * ], [ * ] and [ * ]; and (d) [ * ], and [ * ] and [ * ], including [ * ] and [ * ]. For clarity, [ * ] (whether [ * ]
or [ * ] or [ * ]) shall be [ * ] at [ * ]; however, [ * ] must be [ * ] a [ * ]. Typically, the [ * ] shall also be [ * ] and deemed suitable for [ * ]. 
 1.19 “EMEA” means BMS’ European, Central and Eastern European, Middle Eastern and African commercial territory, consisting of the following countries and regions: Algeria, Andorra,
Austria, Baltic States, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Liechtenstein, Luxembourg, Malta, Morocco, Netherlands, Norway, Poland, Portugal, Romania,
Russia, Saudi Arabia, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Tunisia, Turkey, U.K., Ukraine, Vatican City, Lebanon, Jordan, Syria, Kuwait, Bahrain, Oman, UAE and Qatar. The EMEA also includes: (a) the former Soviet
Union and commonwealth of independent states such as Georgia, Armenia and central Asian republics; and (b) exports from France to English and French speaking African countries not separately identified in the list. For clarity, the specific
list of countries and regions may change to align with any corresponding changes to BMS’ business structures. 
 1.20
“EU” means the European Union, as its membership may be altered from time to time, and any successor thereto. The member countries of the European Union as of the Effective Date are Austria, Belgium, Bulgaria, Cyprus, Czech Republic,
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom. 

1.21 “Executive Officers” means: (a) in the case of Exelixis, the [ * ] of Exelixis; and (b) in the case of
BMS, [ * ]. 
 1.22 “Exelixis ROR Compound” means: 

(a) any Small Molecule Compound that is an ROR Antagonist and is Controlled by Exelixis and/or its Affiliates as of the Effective
Date or during the Term, wherein such compound (i) [ * ] an ROR Antagonist [ * ] or [ * ] and/or [ * ] the [ * ]; (ii) [ * ] an ROR Antagonist [ * ] or [ * ] and/or [ * ] in the [ * ] the [ * ] and is [ * ] a Small Molecule Compound that [
* ] or [ * ] and/or [ * ] an ROR Antagonist [ * ] the [ * ]; or (iii) is [ * ] or [ * ] and such [ * ] an ROR Antagonist (A) [ * ] or [ * ] and/or [ * ] in the [ * ] the [ * ] or (B) [ * ] or [ * ] and/or [ * ] in the [ * ] the [ * ];

 (b) any [ * ] or [ * ] that is an ROR Antagonist and is [ * ] or [ * ] and/or [ * ] the [ * ] or [ * ], wherein such [
* ] (i) [ * ] an ROR Antagonist [ * ] or [ * ] and/or [ * ] the [ * ]; or (ii) [ * ] an ROR Antagonist [ * ] or [ * ] and/or [ * ] in the [ * ] the [ * ]; 
 (c) any [ * ] or a [ * ], wherein such [ * ] is [ * ] or [ * ] and/or [ * ] the [ * ] or [ * ] and such [ * ] an ROR Antagonist (i) [ * ] or [ * ] and/or [ * ] in the [ * ] the [ * ] or
(ii) [ * ] or [ * ] and/or [ * ] in the [ * ] the [ * ]; or 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 4 

 (d) any [ * ], or [ * ] of [ * ] or [ * ]. 

Those ROR Antagonists that are [ * ] Controlled by Exelixis and/or its Affiliates as of the Effective Date are set forth in the Disclosure Letter dated
as of even date herewith. 
 1.23 “Exelixis Licensed Know-How” means all Information (other than
Patents) Controlled by Exelixis and its Affiliates, including Information Controlled jointly with BMS, as of the Effective Date or during the term of this Agreement that: (a) relates to a Licensed Compound, a composition containing a Licensed
Compound, a formulation containing a Licensed Compound, or the manufacture or use of a Licensed Compound; and (b) is [ * ] for BMS to exercise the rights licensed to it under the Agreement or to perform its obligations under the Agreement.

 1.24 “Exelixis Licensed Patents” means all Patents Controlled by Exelixis and its Affiliates, including
Patents Controlled jointly with BMS, as of the Effective Date or during the term of this Agreement that: (a) cover a Licensed Compound, a composition containing a Licensed Compound, a formulation containing a Licensed Compound, or the
manufacture or use of a Licensed Compound; and (b) are [ * ] for BMS to exercise the rights licensed to it under the Agreement or to perform its obligations under the Agreement. 

1.25 “FDA” means the U.S. Food and Drug Administration, and any successor thereto. 

1.26 “GAAP” means U.S. generally accepted accounting principles, consistently applied. 

1.27 “[ * ]” means, with respect to a particular Product in a country, [ * ]: (a) [ * ] such Product (or [ * ]) and
[ * ]; (b) is [ * ] ([ * ] or [ * ]); and (c) is [ * ] or [ * ] a [ * ]. 
 1.28 “IND” means an
Investigational New Drug Application submitted to the FDA in conformance with applicable laws and regulations, or the foreign equivalent of any such application in any other country. 

1.29 “Information” means information, results and data of any type whatsoever, in any tangible or intangible form
whatsoever, including, preclinical data, clinical trial data, databases, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical,
biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures. For clarity, Information does not include any Patents. 

1.30 “Invention” means any and all inventions and improvements, whether or not patentable, that are conceived or reduced
to practice or otherwise made by or on behalf of a Party (and/or its Affiliates) in the performance of its obligations, or the exercise of its rights, under this Agreement. 
 1.31 “Joint Invention” means any Invention invented or discovered jointly by or on behalf of the employee(s), contractor(s) or agent(s) of both Parties (and/or their Affiliates).

 1.32 “Joint Research Committee” or “JRC” means the committee described in
Section 2.1. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 5 

 1.33 “Knowledge” means, with respect of a Party, the [ * ] facts and
information [ * ], or any [ * ] of, or [ * ], [ * ], [ * ] execution of this Agreement. For purposes of this definition, [ * ] means any person in the [ * ] of a Party. 
 1.34 “Launch” means, for each Product in each country, the first arm’s-length sale to a Third Party for use or consumption by the public of such Product in such country after
Regulatory Approval of such Product in such country. A Launch shall not include any Product sold for use in clinical trials, for research or for other non-commercial uses, or that is supplied as part of a compassionate use or similar program.

 1.35 “Licensed Compound” means any BMS ROR Compound or Exelixis ROR Compound. 

1.36 “LXR Collaboration Agreement” means the Collaboration Agreement between Exelixis and BMS, executed as of
December 5, 2005, as amended. 
 1.37 “[ * ]” means [ * ] or [ * ] to the [ * ] that [ * ] the [ * ] set
forth in [ * ] of the [ * ]. 
 1.38 “Major European Countries” means France, Germany, Spain, Italy, and the
United Kingdom. 
 1.39 “Major Territory” means each of the following territories: (a) [ * ]. 

1.40 “Manufacturing” means all activities related to the production, manufacture, processing, filling, finishing,
packaging, labeling, inspection, receiving, holding and shipping of Licensed Compounds, Products, or any raw materials or packaging materials with respect thereto, or any intermediate of any of the foregoing, including process and cost optimization,
process qualification and validation, commercial manufacture, stability and release testing, quality assurance and quality control. For clarity, “Manufacture” has a correlative meaning. 

1.41 “Materials” means: (a) Licensed Compounds; and (b) biological materials, including but not limited to
cell-lines, reagents, genes, vectors and constructs, that are in Exelixis’ Control and that were used by Exelixis in the performance of its obligations under the Research Plan. 

1.42 “NDA” means a New Drug Application submitted to the FDA in conformance with applicable laws and regulations.

 1.43 “Net Sales” means the amount invoiced or otherwise billed by BMS, or its Affiliate or sublicensee, for
sales or other commercial disposition of a Product to a Third Party purchaser, less the following to the extent included in such billing or otherwise actually allowed or incurred with respect to such sales: (a) discounts, including cash, trade
and quantity discounts, price reduction programs, retroactive price adjustments with respect to sales of a product, charge-back payments and rebates granted to managed health care organizations or to federal, state and local governments (or their
respective agencies, purchasers and reimbursers) or to trade customers, including but not limited to, wholesalers and chain and pharmacy buying groups; (b) credits or allowances actually granted upon rejections or returns of Products, including
for recalls or damaged 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 6 

 
goods; (c) freight, postage, shipping and insurance charges actually allowed or paid for delivery of Products, to the extent billed; (d) customs duties, surcharges and other
governmental charges incurred in connection with the exportation or importation of a Product; (e) bad debts relating to sales of Products that are actually written off by BMS in accordance with GAAP during the applicable calculation period;
(f) costs due to the factoring of receivables; and (g) taxes, duties or other governmental charges levied on, absorbed or otherwise imposed on sale of Products, without limitation any fees payable under the Health Care Reform Act of 2010,
value-added taxes, or other governmental charges otherwise measured by the billing amount, when included in billing, as adjusted for rebates and refunds, but specifically excluding taxes based on net income of the seller; provided that all of the
foregoing deductions are calculated in accordance with GAAP. 
 Notwithstanding the foregoing, if any Product is sold under a bundled or
capitated arrangement with other BMS products, then, solely for the purpose of calculating Net Sales under this Agreement, any discount on such Products sold under such an arrangement shall be [ * ] for the applicable accounting period. In case of
any dispute as to the applicable [ * ] under the preceding sentence, the determination of same shall be calculated and certified by [ * ], whose decision shall be binding. 
 A sale of a Product is deemed to occur upon invoicing. [ * ]. 
 For sake of clarity and avoidance
of doubt, sales by BMS, its Affiliates or sublicensees of a Product to [ * ]. Any Products [ * ] considered in determining Net Sales hereunder. 

In the event a Product is sold as an end-user product consisting of a combination of active functional elements or as a combined product and/or service,
Net Sales allocable to the Product in each such country, for purposes of determining royalty payments on such Product, shall be determined by mutual agreement reached in good faith by the Parties prior to the end of the accounting period in question
based on an equitable method of determining such Net Sales that takes into account, on a country-by-country basis, variations in potency, the relative contribution of each active agent, component or service, as the case may be, in the combination,
and relative value to the end user of each active agent, component or service, as the case may be. Notwithstanding the foregoing, the Parties agree that, for purposes of this paragraph, drug delivery vehicles, adjuvants, and excipients shall not be
deemed to be “active ingredients” or “active functional elements”. 
 1.44 “[ *
]” means a [ * ] or [ * ] to the [ * ] that [ * ] the [ * ] set forth in [ * ] of the [ * ]. 
 1.45
“Patent” means all: (a) unexpired letters patent (including inventor’s certificates and utility models) which have not been held invalid or unenforceable by a court or other applicable governmental authority of competent
jurisdiction from which no appeal can be taken or has been taken within the required time period (and which have not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or been abandoned in accordance with or as
permitted by the terms of this Agreement or by mutual written agreement), including any substitution, extension, registration, confirmation, reissue, re-examination, supplementary protection certificates, confirmation patents, patent of additions,
renewal or any like filing thereof; (b) pending applications for letters patent which have not been canceled, withdrawn from consideration, finally determined to be unallowable by the applicable governmental authority or court for whatever
reason (and from which no appeal is or can be taken), and/or abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written consent, 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 7 

 
including any continuation, division or continuation-in-part thereof and any provisional or other priority applications; and (c) any international counterparts, and counterparts in any
country, to clauses (a) and (b) above. 
 1.46 “Phase IIb Clinical Trial” means a clinical trial of a
Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens. 

1.47 “Phase III Clinical Trial” means a clinical trial of a Product on sufficient numbers of patients that is designed
to establish that such Product is safe and efficacious for its intended use, and to define warnings, precautions and adverse reactions that are associated with such Product in the dosage range to be prescribed, and to support Regulatory
Approval of such Product or label expansion of such Product. 
 1.48 “Phase IV Clinical Trial” means a product
support clinical trial of a Product commenced after receipt of Regulatory Approval in the country where such trial is conducted. A Phase IV Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and
investigator-sponsored clinical trials studying Product that are approved by BMS and that otherwise fit the foregoing definition. 
 1.49 “Post-Termination Compound” means any ROR Antagonist for which [ * ] such compound in any of the following time periods after the expiration or termination of the Agreement:
(i) within [ * ] thereafter in the event the Agreement expires or terminates prior to the [ * ] anniversary of the Effective Date; (ii) within [ * ] thereafter in the event the Agreement expires or terminates on or after the [ * ]
anniversary and prior to the [ * ] anniversary of the Effective Date; (iii) within [ * ] thereafter in the event the Agreement terminates on or after [ * ] anniversary and prior to the [ * ] anniversary of the Effective Date; and
(iv) within [ * ] in the event the Agreement terminates on or after the [ * ] anniversary of the Effective Date. For clarity, Post-Termination Compounds shall not include: (A) any compound with respect to which [ * ] such compound [ * ]
and [ * ] the [ * ] any [ * ] or [ * ] or [ * ]; or (B) any compound that [ * ] or [ * ] that is [ * ] and that is [ * ] under Article [ * ] of this Agreement. 
 1.50 “Product” means any human pharmaceutical product containing or comprising a Licensed Compound, either alone or with other active ingredients and in all forms, presentations,
formulations and dosage forms. 
 1.51 “Registrational Trial” means, with respect to a given Product, either:
(a) a Phase III Clinical Trial with such Product; or (b) a Phase IIb Clinical Trial that, at the time of commencement, is expected to be the basis for initial Regulatory Approval of such Product. 

1.52 “Regulatory Approval” means any and all approvals (including Drug Approval Applications, supplements, amendments,
pre- and post-approvals, pricing and reimbursement approvals), licenses, registrations or authorizations of any Regulatory Authority, national, supra-national (e.g., the European Commission or the Council of the EU), regional, state or local
regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary for the manufacture, distribution, use or sale of a Product in a regulatory jurisdiction. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 8 

 1.53 “Regulatory Authority” means the applicable national (e.g., the FDA),
supra-national (e.g., the European Commission or the Council of the EU), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity that, in each case, governs the approval of a Product in such
applicable regulatory jurisdiction. 
 1.54 “Research” means the following activities: (a) identifying
Small Molecule Compounds as [ * ] that [ * ] and [ * ] ROR by [ * ]; (b) conducting a [ * ] program to [ * ] such [ * ] to [ * ] that [ * ] and [ * ] ROR (including the conduct of [ * ] and [ * ] studies, and [ * ] studies); and
(c) conducting [ * ] on [ * ] to [ * ] for [ * ] (including the conduct of [ * ] studies, and related [ * ] and [ * ] activities). To avoid confusion, Research does not include the conduct of Development. 

1.55 “Reverted Compound” means: (a) any Licensed Compound that has [ * ] prior to the effective date of termination
of this Agreement; and (b) any Licensed Compound that: (i) has [ * ] prior to the effective date of termination of this Agreement; and (ii) are [ * ]. 
 1.56 “Reverted Compounds License Agreement” has the meaning set forth in Section 11.5(a)(v). 
 1.57 “ROR” means: (a) the RAR-related orphan receptor [ * ] gene, otherwise known as the [ * ] gene, ([ * ]); (b) the RAR-related orphan receptor [ * ] (otherwise known as [ * ]
or [ * ]) and RAR-related orphan receptor [ * ] (otherwise known as [ * ] or [ * ]) proteins encoded by such gene (“[ * ]”); (c) the RAR-related orphan receptor [ * ] (otherwise known as
[RORa) including all RAR-related orphan receptor [ * ] (otherwise known as [ * ]) proteins encoded by such gene (“[ * ]”); and (d) all [ * ] and [ * ] thereof. 

1.58 “ROR Antagonist” means any Small Molecule Compound that (a) directly binds and antagonizes (or
is an inverse agonist of) ROR at the Target Potency Threshold and (b) is specific for ROR, based upon the Target Specificity Threshold.  
 1.59 “Small Molecule Compound” means a small molecule compound [ * ] or [ * ]. For clarity, [ * ], shall be considered Small Molecule Compounds. 

1.60 “Sole Invention” means any Invention invented or discovered solely by or on behalf of a Party (or its Affiliate)
and its employees, contractors and/or agents. 
 1.61 “Success Criteria” has the meaning set forth in
Section 3.3(b). 
 1.62 “Target Potency Threshold” means, with respect to a
Small Molecule Compound, that such Small Molecule Compound [ * ] and [ * ] (or [ * ] of) the activity of ROR with a half maximal inhibitory concentration (“IC50”) of less than or equal to [ * ] in the [ * ] using [
* ]. 
 1.63 “Target Specificity Threshold” means, with respect to a Small Molecule Compound, that such
Small Molecule Compound demonstrates, in a [ * ] or [ * ], [ * ] ROR [ * ], [ * ] (i.e., the RAR-related orphan receptor [ * ] gene, otherwise known as the [ * ] gene, and the protein encoded by such gene) (“ROR [ * ]”). 

1.64 “Territory” means the world. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 9 

 1.65 “Third Party” means any entity other than: (a) Exelixis;
(b) BMS; or (c) an Affiliate of either Party. 
 1.66 “United States” or “U.S.”
means the United States of America, and its territories, districts and possessions. 
 1.67 “Valid Claim”
means: (a) a claim in an issued Patent that has not: (i) expired or been canceled; (ii) been declared invalid by an unreversed and unappealable or unappealed decision of a court or other appropriate body of competent jurisdiction;
(iii) been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or (iv) been abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written agreement of the Parties; or
(b) a claim under an application for a Patent that has been pending [ * ], and, in any case, which has not been canceled, withdrawn from consideration, finally determined to be unallowable by the applicable governmental authority or court for
whatever reason (and from which no appeal is or can be taken), or abandoned. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 10 

 Additional Definitions 
 The following table identifies the location of definitions set forth in various Sections of the Agreement. 
  

			
	 Definition
	  	 Location (Section)

	Alliance Manager	  	2.3(a)
	Bankrupt Party	  	14.6(a)
	[ * ]	  	[ * ]
	[ * ]	  	[ * ]
	BMS Independent Program	  	5.1(b)
	[ * ]	  	[ * ]
	Confidential Information	  	10.1
	Cost-Terminated Patent Right	  	7.7(d)(iii)
	[ * ] Notice	  	[ * ]
	[ * ] Notice	  	[ * ]
	EDI	  	14.11
	[ * ]	  	[ * ]
	Exelixis Sole Patent	  	7.8(a)(i)
	Indemnitee	  	13.3
	JAMS	  	14.3(c)
	Joint Invention Patents	  	7.5(b)
	Joint Product Patent	  	7.8(b)(i)(1)
	Letter Agreement	  	14.4
	[ * ]	  	[ * ]
	Losses	  	13.1
	Other Joint Patent	  	7.8(b)(ii)(1)
	Permitted Use	  	4.2(b)
	Prior CDA	  	10.4
	Proposed Terms	  	14.3(d)
	Research Plan	  	3.3(a)
	ROR Technology	  	4.1
	Royalty Term	  	8.8
	[ * ]	  	[ * ]
	Sales Threshold	  	8.2(b)
	Separable Compounds	  	7.7(a)(v)
	Sole Invention Patents	  	7.5(b)
	Support Memorandum	  	14.3(c)
	Term	  	11.1
	TGR5 License Agreement	  	14.4
	[ * ]	  	[ * ]
	Title 11	  	14.6(a)
	Transfer Addendum	  	4.2(d)
	Unauthorized Invention	  	4.2(c)

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 11 

	2.	GOVERNANCE 

 2.1 Joint
Research Committee. 
 (a) Membership of JRC. The JRC shall be composed of four (4) members. Within [ * ] after
the Effective Date, each Party shall appoint two (2) representatives to the JRC. Each Party may replace its appointed JRC representatives at any time upon written notice to the other Party. Each Party shall designate one (1) of its
representatives as co-chairperson of the JRC. Each of the co-chairpersons shall be responsible, on an alternating basis with the BMS co-chairperson having responsibility with respect to the initial meeting, for working with the Alliance Managers to
schedule meetings, prepare and circulate an agenda in advance of each meeting, and to prepare and issue minutes of each meeting within [ * ] thereafter. Any JRC member may add topics to the draft agenda. 

(b) Decision-making. The two (2) JRC representatives of each Party shall collectively have one (1) vote, and the JRC
shall operate by unanimous consent of all JRC members present and in accordance with the principles set forth in this Article 2. The JRC shall not have any authority or jurisdiction to amend, modify, or waive compliance with this Agreement,
any of which shall require mutual written agreement of the Parties. In the event of a dispute between the Parties with regard to the performance of the Collaboration, the matter shall be first referred to the Alliance Managers for resolution. If
these two (2) individuals are unable to resolve the dispute, then the matter shall be elevated to the [ * ] of Exelixis and the [ * ] of BMS (or in either case a direct report of such individual). If these two (2) individuals are unable to
resolve the dispute, then, subject to the last sentence of this Section 2.1(b) and to Section 2.1(c), [ * ] shall have the final decision for [ * ] disputes relating to the [ * ] or [ * ] of the [ * ], so long as such
decision does not [ * ] or conflict with the terms of the Agreement, the Parties shall mutually agree as to the [ * ] of the [ * ] of [ * ] that [ * ] the [ * ] under the [ * ], and [ * ] shall have the final decision with respect to [ * ] disputes
with respect to the [ * ], so long as such decision does not conflict with the terms of the Agreement. Notwithstanding anything to the contrary, no decision by a Party shall (i) require the other Party to: (1) [ * ] or [ * ] that such
other Party [ * ] or [ * ]; (2) [ * ] that are [ * ] or [ * ] those [ * ] the [ * ]; or (3) [ * ] any [ * ] (e.g., [ * ] of the [ * ] for [ * ] in the [ * ] for [ * ]) in connection with [ * ] of [ * ] the [ * ], or [ * ] associated with
such [ * ]; or (ii) amend, modify, or waive such Party’s compliance with, this Agreement, any of which shall require mutual written agreement of the Parties. 
 (c) Exceptions to Decision-making. Notwithstanding anything to the contrary, [ * ] shall not have the final decision with respect to any dispute involving any of the following: (i) [ * ] of
the [ * ] the [ * ] and [ * ] of [ * ] the [ * ] and [ * ] of [ * ]; (ii) changing the [ * ]; (iii) changing [ * ] for [ * ] in a manner that [ * ] for [ * ] that are [ * ] with [ * ] for the [ * ] the [ * ]; (iv) whether the [ * ] by
[ * ] pursuant to [ * ] that a [ * ] the [ * ]; (v) changing the [ * ] in a manner that [ * ] that are [ * ] with [ * ] for the [ * ] the [ * ]; (vi) whether the [ * ] by [ * ] pursuant to [ * ] that a [ * ] the [ * ]; (vii) changing
the [ * ] or the [ * ]; or (viii) changing the [ * ] the [ * ] so as to modify [ * ] (including [ * ]) under the [ * ], or the [ * ] associated therewith. 
 (d) Responsibilities of the JRC. The JRC shall be responsible for the overall planning and execution of the Collaboration and the approval and oversight of the Research Plan.

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 12 

 
At its meetings, the JRC shall evaluate the Parties’ progress in carrying out the Research Plan and the data generated by the Parties in the course of carrying out the Research Plan, shall
discuss and approve project prioritization within the Research Plan, shall discuss and approve any revisions to the Research Plan, and shall perform those activities specifically described in this Agreement. To the extent necessary to carry out its
responsibilities, a Party’s JRC members shall be granted access to the other Party’s Confidential Information relevant to any decision required to be made by the JRC. 

2.2 Meetings of JRC. During the Collaborative Research Period, the JRC shall meet [ * ] by audio or video teleconference and, at a
minimum, [ * ] in person (which in-person meeting shall be held on an alternating basis in New Jersey and in San Francisco). With the consent of the representatives of each Party serving on the JRC, other representatives of each Party may attend
meetings of the JRC as nonvoting observers (provided such representatives: (i) have contractual confidentiality obligations to such Party that are at least as stringent as those set forth in this Agreement; and (ii) are under intellectual
property assignment obligations to such Party in accordance with Section 7.5(c)). Meetings of the JRC shall be effective only if at least one (1) representative of each Party is present or participating. Each Party shall be
responsible for all of its own expenses of participating in JRC meetings. The Parties shall endeavor to schedule meetings of the JRC at least [ * ] in advance. Upon the conclusion of the Collaborative Research Period, the JRC shall be discontinued.

 2.3 Alliance Managers. 
 (a) Appointment. Each of the Parties shall appoint an individual (each, an “Alliance Manager”) who possesses a general understanding of the scientific and business issues relevant
to this Agreement. Each Party may change its designated Alliance Manager from time to time upon prior written notice to the other Party. Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager by
prior written notice to the other Party. 
 (b) Responsibilities. The Alliance Managers shall use good faith efforts to
attend all JRC meetings and support the co-chairpersons of the JRC in the discharge of their responsibilities. Alliance Managers shall be nonvoting participants in JRC meetings. An Alliance Manager may bring any matter to the attention of the JRC if
such Alliance Manager reasonably believes that such matter warrants such attention. Each Alliance Manager shall be charged with creating and maintaining a collaborative work environment within the JRC. In addition, each Alliance Manager:
(a) shall be the point of first referral in all matters of conflict resolution; (b) shall identify and bring disputes to the attention of the JRC in a timely manner; (c) shall plan and coordinate cooperative efforts and internal and
external communications; and (d) shall take responsibility for ensuring that governance activities, such as the conduct of required JRC meetings and production of meeting minutes, occur as set forth in this Agreement, and that relevant action
items resulting from such meetings are appropriately carried out or otherwise addressed. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 13 

	3.	RESEARCH COLLABORATION. 

3.1 Overview. The general goals and intent of the research portion of the Collaboration are to apply each Party’s technology
to discover, optimize and characterize ROR Antagonists that may be developed into Products by BMS. Each Party shall use Diligent Efforts to carry out its research responsibilities in accordance with the allocation of duties set forth in the Research
Plan, including responsibilities for [ * ], [ * ] and [ * ] of Licensed Compounds and activities to be conducted by the Parties that lead to the submission by Exelixis of data to BMS [ * ]. 

3.2 Collaborative Research Period. Subject to termination of this Agreement pursuant to Section 11.2 or 11.3
(which will in turn terminate the Collaborative Research Period), the Collaborative Research Period shall begin on the Effective Date and shall, unless otherwise agreed by the Parties, terminate as follows (such period, the “Collaborative
Research Period”): 
 (a) In the event that [ * ] as of third (3rd) anniversary of the Effective Date, then
the Collaborative Research Period shall end on such third (3rd) anniversary of the Effective Date. 

(b) In the event that [ * ] prior to the third (3rd) anniversary of the Effective Date, then the
Collaborative Research Period shall end upon the earlier of (i) the second (2nd) anniversary of the date on which in such series of Licensed Compounds has achieved [ * ], or (ii) achievement of the first [ * ] for a Licensed Compound. 

During the Collaborative Research Period, each Party shall use Diligent Efforts to perform the tasks assigned to it in the Research Plan then in effect.
For clarity, upon [ * ], Exelixis shall be deemed to have fulfilled its obligations under the Research Plan. 
 3.3 Research
Plan; Success Criteria. 
 (a) The Parties have agreed in writing upon a detailed plan for the research to be carried
out by the Parties during the Collaborative Research Period, which is set forth in the Disclosure Letter and incorporated herein by reference (the “Research Plan”). The Research Plan includes each Party’s respective obligations
in furtherance of the research portion of the Collaboration and timelines for completion of key stages. The JRC shall review the Research Plan at least [ * ] and may propose and approve, subject to Sections 2.1(b) and 2.1(c), a revised
version of the Research Plan that is consistent with the terms of this Agreement. Once approved by the JRC, such revised Research Plan shall replace the prior Research Plan. 
 (b) The Research Plan shall also contain criteria that a Licensed Compound must satisfy in order for BMS to make the [ * ] decision (each set of criteria, “Success Criteria”). Any
Success Criteria that are not reasonably ascertainable or completely known as of the Effective Date, or requiring adjustment based on results obtained during the conduct of the Research Plan, shall be supplemented and/or modified as approved by
mutual agreement of the JRC from time to time as appropriate. 
 3.4 Activities and Costs under the Research Plan.

 (a) The Parties intend: (i) for Exelixis to perform [ * ] activities during the “[ * ]”

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 14 

 
phase of the Research Plan, including [ * ] of certain [ * ], known as “[ * ]” and “[ * ]” in the [ * ], that were [ * ] or [ * ] pursuant to the [ * ] (with [ * ] the [ * ]
to [ * ] activities with respect to such [ * ] pursuant to the [ * ]); (ii) for Exelixis to perform the [ * ] activities in “[ * ]” phase of the Research Plan, which may include [ * ] of [ * ] that were [ * ] and [ * ] as [ * ] to the
[ * ]; and (iii) for the Parties, after [ * ], to jointly perform the “[ * ]” phase of the Research Plan, in each case as set forth in more detail in the Research Plan. Exelixis shall provide no less than the minimum number of FTEs
for the periods and activities set forth in the Research Plan, and shall continue to support the Research Plan using Diligent Efforts upon the expiration of any such period until the conclusion of the Collaborative Research Period, and BMS shall
provide adequate resources to meet its activities set forth in the Research Plan. 
 (b) Each Party shall bear its own
internal and out-of-pocket costs and expenses incurred in connection with the conduct of the activities assigned to it under the Research Plan. 
 3.5 [ * ]. Promptly after the Parties’ activities pursuant to the Research Plan generate data demonstrating that a particular series of Licensed Compounds meets the Success Criteria for [ * ],
and subsequent to activities in Section 3.7, Exelixis shall submit such data to BMS. BMS shall promptly (and in good faith) review such data, and, within [ * ] of such submission, shall notify Exelixis in writing if BMS believes in good
faith that such data do not demonstrate that such series of Licensed Compounds [ * ], which notice shall specify the deficiencies in such data that cause it not to demonstrate that such series of Licensed Compounds [ * ] (such notice, a “[ *
] Notice”). If Exelixis does not receive [ * ] Notice from BMS by the end of such 30-day period, then BMS will, as of the end of such 30-day period, be deemed to have agreed that the series of Licensed Compounds [ * ] (“[ *
]”) and BMS shall be obligated to [ * ] set forth in Section [ * ] no later than [ * ] after the end of such period. If Exelixis receives [ * ] Notice within such [ * ] period and it disagrees with BMS’ assessment of such data,
then such dispute shall be resolved by a mutually acceptable independent Third Party expert. Such Third Party expert shall determine, within [ * ] of receipt of the data submitted by Exelixis to BMS pursuant to this Section 3.5 and the [
* ], whether such data demonstrate that such series of Licensed Compounds [ * ], and the Parties agree that such Third Party expert’s determination on this issue shall be final, binding, and determinative. The Party against whom the Third Party
expert rules shall bear all costs of such Third Party determination. If such Third Party expert determines that data submitted by Exelixis to BMS pursuant to this Section 3.5 demonstrate that such series of Licensed Compounds [ * ], then
BMS will, as of the date of such determination, be deemed to have made a [ * ] and BMS shall be obligated to [ * ] set forth in Section [ * ] no later than [ * ] after the date of such determination. If such Third Party expert determines that
data submitted by Exelixis to BMS pursuant to this Section 3.5 does not demonstrate that such series of Licensed Compounds [ * ], then [ * ] will not have occurred and the parties shall continue to work under the Research Plan in order
to [ * ]. 
 3.6 [ * ]. Promptly after the Parties’ activities pursuant to the Research Plan generate data
demonstrating that a particular Licensed Compound [ * ], Exelixis shall submit such data to BMS. BMS shall promptly (and in good faith) review such data, and, within [ * ] of such submission, shall notify Exelixis in writing if BMS believes in good
faith that such data do not demonstrate that such Licensed Compound [ * ], which notice shall specify the deficiencies in such data that cause it not to demonstrate that such Licensed Compound [ * ] (such notice, an “[ * ] Notice”).
If Exelixis does not receive [ * ] Notice from BMS by the end of such [ * ] period, then BMS will, as of the end of such [ * ] period, be deemed to have agreed the Licensed Compound [ * 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 15 

 
] (“[ * ]”) and BMS shall be obligated to [ * ] set forth in Section [ * ] no later than [ * ] after the end of such period. If Exelixis receives [ * ] Notice within such
[ * ] period and it disagrees with BMS’ assessment of such data, then such dispute shall be resolved by a mutually acceptable independent Third Party expert. Such Third Party expert shall determine, within [ * ] of receipt of the data submitted
by Exelixis to BMS pursuant to this Section 3.6 and [ * ], whether such data demonstrate that such Licensed Compound [ * ], and the Parties agree that such Third Party expert’s determination on this issue shall be final, binding,
and determinative. The Party against whom the Third Party expert rules shall bear all costs of such Third Party determination. If such Third Party expert determines that data submitted by Exelixis to BMS pursuant to this Section 3.6
demonstrate that such Licensed Compound [ * ], then BMS will, as of the date of such determination, be deemed to have made a [ * ] and BMS shall be obligated to make the milestone payment set forth in Section [ * ] no later than [ * ] after
the date of such determination. If such Third Party expert determines that data submitted by Exelixis to BMS pursuant to this Section 3.6 does not demonstrate that such Licensed Compound [ * ], then [ * ] will not have occurred and the
parties shall continue to work under the Research Plan in order to [ * ]. 
 3.7 Review of Licensed Compounds. Prior to
any determination whether a Licensed Compound meets the Success Criteria for [ * ], Exelixis shall review the results of all [ * ] assays for [ * ] conducted by either Party for a compound that is expected to progress to [ * ]. BMS shall provide
Exelixis with the results of all [ * ] assays conducted by or on behalf of relating to [ * ] for each [ * ] Licensed Compound, and sufficient samples of each [ * ] Licensed Compound to have such assays conducted. Exelixis may use such results and
samples for the sole purpose of performing assays to verify that such [ * ] Licensed Compound [ * ] of [ * ] any [ * ] for [ * ] to any [ * ] (“[ * ]”). Exelixis shall be responsible for having such assays conducted [ * ]
associated with such assays. If Exelixis notifies BMS in writing within [ * ] of receiving a sample of a submitted [ * ] Licensed Compound that such Licensed Compound [ * ], then BMS shall [ * ] or [ * ] such Licensed Compound, and [ * ] to [ * ]
such Licensed Compound shall [ * ] ([ * ] to such Licensed Compound); provided, however, that BMS [ * ] such Licensed Compound [ * ] in [ * ] to [ * ] the [ * ] such Licensed Compound. For clarity, (i) nothing in this
Section 3.7 shall be [ * ] conducting screening activities, at any time, with respect to Licensed Compounds in order to determine whether Licensed Compounds [ * ], and (ii) BMS may [ * ] and [ * ] with respect to any such submitted
[ * ] Licensed Compound during such review period prior to receiving any such written notice from Exelixis. In the event that Exelixis does not provide written notice to BMS with respect to the [ * ] submitted [ * ] Licensed Compound within such [ *
] period, then BMS shall [ * ] and [ * ] such Licensed Compound [ * ] and [ * ] in [ * ]. Notwithstanding the foregoing, Exelixis shall use commercially reasonable efforts to notify BMS as soon as practicable in the event that Exelixis becomes aware
in the course of performing its obligations under the Research Plan during the Collaborative Research Period that a Licensed Compound [ * ]. 
 3.8 Obligations of Parties. Exelixis and BMS shall provide the JRC and its authorized representatives with reasonable access during regular business hours to all records, documents, and Information
relating to the performance under the Collaboration, which the JRC may reasonably require in order to perform its obligations hereunder, provided that if such documents are under a bona fide obligation of confidentiality to a Third Party, then
Exelixis or BMS, as the case may be, may withhold access thereto to the extent necessary to satisfy such obligation. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 16 

 3.9 Collaboration Guidelines. Subject to the terms of this Agreement, the activities
and resources of each Party shall be managed by such Party, acting independently and in its individual capacity. The relationship between Exelixis and BMS is that of independent contractors, and shall not constitute a partnership, joint venture or
agency, and neither Party shall have the power to bind or obligate the other Party in any manner, other than as is expressly set forth in this Agreement. 
 3.10 Conduct of Research. The Parties shall use Diligent Efforts to conduct their respective tasks throughout the Collaboration and shall conduct the Collaboration in good scientific manner, and in
compliance in all material respects with the requirements of applicable laws, rules and regulations and all applicable good laboratory practices to attempt to achieve their objectives as efficiently and expeditiously as reasonably practicable. Each
Party may use its Affiliates or subcontractors, contract manufacturers, services providers or other Third Parties to complete its research responsibilities under the Research Plan, except that Exelixis shall not be permitted to use Third Party
contractors to complete the respective tasks of the minimum Exelixis FTEs specifically set forth in the Research Plan without the approval of the JRC. 
 3.11 Records. Each Party shall maintain complete and accurate records of all work conducted under the Collaboration and all results, data and developments made pursuant to its efforts under the
Collaboration. Such records shall be complete and accurate and shall fully and properly reflect all work done and results achieved in the performance of the Collaboration in sufficient detail and in good scientific manner appropriate for patent and
regulatory purposes. Each Party shall maintain such records for a period of [ * ] after such records are created; provided that the following records may be maintained for a longer period, in accordance with each Party’s internal policies on
record retention, provided that in no case shall such period be shorter than [ * ] from the date of creation of such records: (a) scientific notebooks; and (b) any other records that the other Party reasonably requests be retained in order
to ensure the preservation, prosecution, maintenance or enforcement of intellectual property rights. Either Party shall have the right to review and copy such records of the other Party at reasonable times to the extent necessary or useful for it to
conduct its obligations or enforce its rights under this Agreement. 
 3.12 Reports. During the Collaborative Research
Period, each Party shall report to the JRC no less than [ * ] and shall submit to the other Party and the JRC [ * ] written progress report summarizing the work performed under the Collaboration. If reasonably necessary for a Party to perform its
work under the Collaboration or to exercise its rights under the Agreement, such Party may request that the other Party provide more detailed information and data regarding such results reported by such other Party, and such other Party shall
promptly provide the requesting Party with information and data as is reasonably related to such request, including any records created by a Party pursuant to Section 3.11. All such reports shall be considered Confidential Information of
the Party providing same. 
  

	4.	TRANSFER OF ROR TECHNOLOGY 

4.1 General. For a period beginning on the Effective Date and ending [ * ] after the end of the Collaborative Research Period,
Exelixis shall use Diligent Efforts to transfer to BMS, solely in accordance with Section 4.2, all items of Materials or Information that are in Exelixis’ possession and Control and that are [ * ] for BMS to research or clinically
develop or manufacture Licensed 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 17 

 
Compounds (such Information and Materials, “ROR Technology”); provided that subsequent to such [ * ] period, Exelixis will use commercially reasonable efforts to transfer
Information and Materials that are requested by BMS for purposes of making a regulatory filing or patent application and that are in Exelixis’ possession and Control (as of the date of such request). BMS may request such a transfer in writing
pursuant to Section 4.2. Additionally, BMS may request that Exelixis provide a reasonable amount of on-site advice or support in connection with the foregoing transfer until the date which is [ * ] subsequent to the [ * ], and BMS shall
reimburse Exelixis for reasonable travel costs incurred 
 4.2 Transfer of ROR Technology. Exelixis shall transfer to
BMS, upon prior written approval by the Parties, reasonable quantities of Information and Materials included in the ROR Technology solely as described below. 
 (a) Ownership. Except as otherwise provided in the Agreement, all rights, title and interest in and to such Information and Materials that are transferred by Exelixis to BMS shall remain with
Exelixis. All such Information and Materials shall be considered the Confidential Information of Exelixis and shall be subject to Article 10 of the Agreement. 
 (b) Permitted Use. BMS shall use such Information and Materials solely for performing its obligations under the Research Plan and exercising its right to perform the BMS Independent Program,
subject to any additional limitations due to Exelixis’ obligations to Third Parties relating to such Information or Materials (with such limitations being set forth in the applicable Transfer Addendum) (the “Permitted Use”).
BMS shall not transfer, deliver or disclose any of the Materials to any Third Party, other than its Affiliates or bona fide collaborators or third party contract service providers, without Exelixis’ prior written consent, except as otherwise
stipulated in the Transfer Addendum. The Materials shall not be used in humans, except as otherwise contemplated by the Agreement. Any unused Materials supplied by Exelixis shall be returned to Exelixis or destroyed as agreed upon in writing by the
Parties. 
 (c) Unauthorized Use. The Parties do not intend for BMS to use the Materials other than for the Permitted
Use. If BMS or its Affiliates or other transferees use the Information or Materials outside of the Permitted Use, and any inventions, improvements, discoveries or data arise (or result) from such unauthorized use (such inventions, improvements,
discoveries and data, and all intellectual property rights related thereto, collectively the “Unauthorized Inventions”), then: (i) BMS shall promptly and fully disclose all such Unauthorized Inventions to Exelixis in writing;
(ii) BMS shall comply with the terms of any upstream license agreement between Exelixis and a Third Party with respect to such Unauthorized Use of Materials; and (iii) Exelixis may pursue all rights and remedies it may have under this
Agreement, or at law or in equity, with respect to any breach of BMS’ obligation of Permitted Use (and creation of any Unauthorized Inventions). 
 (d) Transfer Addendum. Each transfer shall occur through the execution of an agreement substantially in the form of Exhibit 4.2 (each, a “Transfer Addendum”), which is
incorporated by reference into the Agreement. After receiving BMS’ written request for a particular item of ROR Technology, Exelixis shall prepare and submit a Transfer Addendum listing the Information and Materials to be transferred to BMS.
Upon written approval of such Transfer Addendum by the Parties, the Information and Materials shall be transferred to BMS within [ * ]. For clarity, the intent of the Parties is to provide BMS with the ability to use Materials and

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 18 

 
Information for the Permitted Use and without additional restrictions other than those set forth in any applicable agreements between Exelixis and a Third Party, and as such, (i) no Transfer
Addendum shall contain terms that are inconsistent with this Agreement, and (ii) Exelixis shall not unreasonably withhold its signature on a Transfer Addendum to prevent BMS from obtaining access to Materials or Information where such request
by BMS is consistent with Section 4.1 and this Section 4.2. 
  

	5.	RESEARCH, DEVELOPMENT, MANUFACTURING & COMMERCIALIZATION OF PRODUCTS 

5.1 Research, Development, & Manufacturing of Products 

(a) Scope. After the end of the Collaborative Research Period, BMS shall have sole control and responsibility for the Research
(which Research shall solely be conducted pursuant to the BMS Independent Program), Development, Manufacture (including formulation) and Commercialization of all Products. BMS shall bear all costs and expenses associated with such Research,
Development, Manufacture (including formulation) and Commercialization of Products. 
 (b) BMS Independent Program. After
the end of the Collaborative Research Period, BMS shall have the right to, at its sole expense, to conduct Research upon Licensed Compounds in accordance with, and solely to the extent permitted by, the license set forth in
Section 7.1(b) (such Research, the “BMS Independent Program”). BMS shall provide Exelixis with a written description of each ROR Antagonist that is optimized under the BMS Independent Program. Each such ROR Antagonist
shall be deemed [ * ] unless it qualifies as [ * ] on account of satisfying the definition set forth in Section [ * ]. 

(c) Diligence. During the BMS Independent Program, BMS shall use Diligent Efforts to conduct Research to advance at least one
Licensed Compound to meet the Success Criteria for [ * ]. BMS shall use Diligent Efforts to Develop at least one Product in each country in the Major Territory, and Commercialize each Product for each indication for which it receives Regulatory
Approval; provided, however, that BMS may satisfy its diligence obligations by sublicensing the Development and Commercialization of a Product to a Third Party pursuant to the terms of this Agreement. Exelixis may notify BMS in writing if Exelixis
in good faith believes that BMS is not meeting its diligence obligations set forth in this Section 5.1(c), and the Parties shall meet and discuss the matter in good faith. Exelixis may further request review of BMS’ records
generated and maintained as required under Section 5.1(d) below. 
 (d) Records. BMS shall maintain complete
and accurate records of all Research, Development, Manufacturing and Commercialization conducted by it or on its behalf related to each Product, and all Information generated by it or on its behalf in connection with Development under this Agreement
with respect to each such Product. BMS shall maintain such records at least until the later of: (i) [ * ] after such records are created, or (ii) [ * ] after the Launch of the Product to which such records pertain; provided that the
following records may be maintained for a longer period, in accordance with each Party’s internal policies on record retention: (i) scientific notebooks and (ii) any other records that Exelixis reasonably requests be retained in order
to ensure the preservation, prosecution, maintenance or enforcement of intellectual property rights. Such records shall be at a level of detail appropriate for patent and regulatory purposes. Exelixis shall have the

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 19 

 
right to review and copy such records of BMS at reasonable times to the extent necessary or useful for Exelixis to conduct its obligations or enforce its rights under this Agreement. 

(e) Reports. Beginning [ * ] after the end of the Collaborative Research Period, and every [ * ] thereafter during the term of the
Agreement, BMS shall submit to Exelixis a written progress report summarizing the Research, Development, Manufacturing and Commercialization performed by or on behalf of BMS with respect to Products. If reasonably necessary or useful for Exelixis to
exercise its rights under this Agreement, Exelixis may request that BMS provide more detailed Information and data regarding such reports by BMS, and BMS shall promptly provide Exelixis with Information and data as is reasonably related to such
request, at Exelixis’ expense. All such reports shall be considered Confidential Information of BMS. 
 5.2 Standards of
Conduct. BMS shall perform, or shall ensure that its Affiliates, sublicensees and Third Party contractors perform, all Research, Development, Manufacturing and Commercialization activities in a good scientific and ethical business manner and in
compliance with applicable laws, rules and regulations. 
  

	6.	REGULATORY 

 6.1
Regulatory Lead Party. BMS shall have sole responsibility for (and bear all costs and expenses associated with) all regulatory activities regarding Products. BMS shall also have sole responsibility for (and bear all costs and expenses associated
with) worldwide pharmacovigilance for each Product. BMS and its Affiliates shall have sole responsibility for all pricing and reimbursement approval proceedings relating to any Product in the Territory. 

6.2 Ownership of Regulatory Dossier. BMS will own all regulatory filings for such Product in order to facilitate BMS’
interactions with Regulatory Authorities. BMS shall prepare and draft all filings (including any supplements or modifications thereto and including the preparation of any electronic submission of a Drug Approval Application) to Regulatory
Authorities in each such country for such Product. 
 6.3 Recalls in the Territory. Any decision to initiate a
recall or withdrawal of a Product in the Territory shall be made by BMS. In the event of any recall or withdrawal, BMS shall take any and all necessary action to implement such recall or withdrawal in accordance with applicable law, with assistance
from Exelixis as reasonably requested by BMS. The costs of any such recall or withdrawal in the Territory shall be borne solely by BMS. 
  

	7.	LICENSES; INTELLECTUAL PROPERTY 

 7.1 Licenses to BMS. Subject to the terms of this Agreement: 
 (a)
Collaborative Research Period (Non-Sublicensable to Non-Affiliates). During the Collaborative Research Period, Exelixis hereby grants to BMS a co-exclusive, worldwide, royalty-free license (with the right to sublicense to its Affiliates, but
without the right to sublicense to Third Parties except with prior written consent of Exelixis), under the Exelixis Licensed Know-How and the Exelixis Licensed Patents, solely to perform, or have performed pursuant to Section 3.10, the
research tasks assigned to BMS pursuant to the Research Plan. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 20 

 (b) BMS Independent Program (Sublicensable to Non-Affiliates). During the period
beginning with the end of the Collaborative Research Period and ending on the expiration or earlier termination of this Agreement, Exelixis hereby grants to BMS, an exclusive, worldwide, royalty-free license (with the right to sublicense to its
Affiliates, Third Party contract research providers and manufacturers, and bona fide collaborators), under the Exelixis Licensed Know-How and the Exelixis Licensed Patents, to make, have made, import and use for Research any: (i) Licensed
Compounds (subject to Section 3.7) that have achieved a [ * ] by the end of the Collaborative Research Period; (ii) Licensed Compounds (subject to Section 3.7) that have achieved a [ * ] by the end of the Collaborative
Research Period; (iii) Licensed Compounds (subject to Section 3.7) that have achieved the [ * ] described in the Research Plan by the end of the Collaborative Research Period; and (iv) [ * ] the Licensed Compounds [ * ] in [ *
], including [ * ] that is created under [ * ] for [ * ]. 
 (c) Clinical Development and Commercialization. Exelixis
hereby grants to BMS, effective upon BMS’ timely payment of the milestone payment set forth in Section 8.2(a)(i)(2), an exclusive, worldwide, royalty-bearing license (with the right to sublicense), under the Exelixis Licensed
Know-How and Exelixis Licensed Patents, to make, have made, use, Develop, import, sell, offer to sell and have sold Products. 

(d) Exelixis Retained Rights. Exelixis retains all rights to use the Exelixis Licensed Know-How and Exelixis Licensed Patents
except those expressly granted to BMS on an exclusive basis under the terms of this Agreement. In addition, notwithstanding the exclusive licenses granted to BMS pursuant to Section 7.1, Exelixis retains the right under the Exelixis
Licensed Patents and the Exelixis Licensed Know-How to make, have made, use, and test Licensed Compounds solely for internal research purposes. 
 (e) BMS Covenants. BMS hereby covenants that BMS shall not (and shall ensure that any of its permitted sublicensees shall not) use any Exelixis Licensed Know-How or Exelixis Licensed Patents for a
purpose other than that expressly permitted in Section 7.1 or 11.5(b). 
 7.2 License to Exelixis for
Collaboration Research. Subject to the terms of this Agreement, BMS hereby grants Exelixis a co-exclusive, worldwide, royalty-free license (with the right to sublicense to Affiliates, but without the right to sublicense to Third Parties except
with prior written consent of BMS), under the BMS Licensed Know-How and BMS Licensed Patents, solely to perform, or have performed pursuant to Section 3.10, the research tasks assigned to Exelixis pursuant to the Research Plan. Exelixis
hereby covenants that Exelixis shall not (and shall ensure that any of its permitted sublicensees shall not) use any BMS Licensed Know-How or BMS Licensed Patents for a purpose other than that expressly permitted in this Section 7.2 or
11.5(a). 
 7.3 No Additional Licenses. Except as expressly provided in Sections 4.2, 7.1, 7.2, and Article
11, nothing in this Agreement grants either Party any right, title or interest in and to the intellectual property rights of the other Party (either expressly or by implication or estoppel). For clarity, the licenses granted in
Section 7.1 by Exelixis to BMS do not give BMS any right or license (a) to incorporate into any Product (e.g., as a combination product) any compound that is Controlled by Exelixis and that is not a Licensed Compound or (b) to
perform any research that is directed to identifying, characterizing, developing or otherwise pursuing any Small Molecule Compound that is 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 21 

 
not a Licensed Compound. For clarity, the licenses granted in Section 11.5 by BMS to Exelixis do not give Exelixis any right or license (a) to incorporate into any Product (e.g.,
as a combination product) any compound that is Controlled by Exelixis and that is not a Reverted Compound or (b) to perform any research that is directed to identifying, characterizing, developing or otherwise pursuing any small molecule
compound that is not a Reverted Compound. 
 7.4 Sublicensing. Each Party shall provide the other Party with the name of
each permitted sublicensee of its rights under this Article 7 and a copy of the applicable sublicense agreement; provided that each Party may redact confidential or proprietary terms from such copy, including financial terms. The sublicensing
Party shall remain responsible for each permitted sublicensee’s compliance with the applicable terms and conditions of this Agreement. Each sublicense granted by a Party of its rights under this Article 7 to a party who is an Affiliate
of such Party at the time such license is granted shall terminate immediately upon such party ceasing to be an Affiliate of such Party. 
 7.5 Ownership. 
 (a) The inventorship of all Sole Inventions and
Joint Inventions shall be determined under the U.S. patent laws. 
 (b) Each Party shall own the entire right, title and
interest in and to any and all of its Sole Inventions, and Patents claiming only such Sole Inventions (and no Joint Inventions) (“Sole Invention Patents”). BMS and Exelixis shall be joint owners in and to any and all Joint
Inventions and Patents claiming such Joint Inventions (“Joint Invention Patents”). BMS and Exelixis as joint owners each shall have the right to exploit and to grant licenses under such Joint Inventions, and where exercise of such
rights require, under the laws of a country, with the consent of the other Party (such consent not to be unreasonably withheld, delayed or conditioned) unless otherwise specified in this Agreement (including where such rights are exclusively
licensed to the other Party hereunder). 
 (c) All employees, agents and contractors of each Party shall be under written
obligation to assign any inventions and related intellectual property to the Party for whom they are employed or are providing services. 
 (d) The Parties acknowledge and agree that this Agreement shall be deemed to be a “Joint Research Agreement” as defined under 35 U.S.C. 103(c). 

7.6 Disclosure. Each Party shall submit a written report to the other Party no less frequently than within [ * ] of the end of
each [ * ] describing any Sole Invention or Joint Invention arising during the prior [ * ] in the course of the Agreement which it believes may be patentable or at such earlier time as may be necessary to preserve patentability of such invention.
Each Party shall provide to the other Party such assistance and execute such documents as are reasonably necessary to permit the filing and prosecution of such patent application to be filed on such Sole Invention or Joint Invention, or the
issuance, maintenance or extension of any resulting Patent. 
 7.7 Patent Prosecution and Maintenance; Abandonment.

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 22 

 (a) Joint Patent Committee. 

(i) Establishment & Meetings. Promptly after the Effective Date (as defined in the TGR5 License Agreement), the Parties
shall establish a committee (the “Joint Patent Committee” or “JPC”). The JPC shall be composed of at least one (1) representative from each Party, at least one of which shall be a patent counsel for such Party.
Each Party may change its representative(s) by giving the other Party at least [ * ] prior written notice. The JPC shall meet within [ * ] after the Effective Date (as defined in the TGR5 License Agreement), and once per [ * ] thereafter, or as may
be requested by either Party as necessary, by teleconference, videoconference or in person (as determined by the JPC). 

(1) Duties. Promptly after the Effective Date (as defined in the TGR5 License Agreement), [ * ] shall oversee (subject to
Sections 7.7(a)(ii), (iv) and (v) below) the preparation, filing, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of all [ * ] Patents, [ * ] Patents Controlled by [ * ], and
[ * ] Patents that in each case are [ * ] (the “[ * ] Patents”), provided that, unless otherwise agreed by the Parties, such responsibilities shall be carried out by: (A) [ * ] by [ * ] the [ * ], unless there exists [ *
] of [ * ] and [ * ]; (B) [ * ] by [ * ], but only in the case where [ * ] described in subsection (A) had [ * ] of [ * ]; or (C) [ * ] in conjunction with [ * ] described in the preceding subsection (A) or (B), as applicable. [
* ], or [ * ], shall provide [ * ] with an update of the filing, prosecution and maintenance status for each of the [ * ] Patents on a periodic basis, and shall use commercially reasonable efforts to consult with and cooperate with [ * ] with
respect to the filing, prosecution and maintenance of the [ * ] Patents, including providing [ * ] with drafts of proposed filings to allow [ * ] a reasonable opportunity for review and comment before such filings are due. [ * ], or [ * ], shall
provide to [ * ] copies of any papers relating to the filing, prosecution and maintenance of the [ * ] Patents promptly upon their being filed and received. 
 (2) Decisions. Subsequent to the Effective Date (as defined in the TGR5 License Agreement), in the event of a dispute between the Parties with regard to the preparation, filing, prosecution
(including any interferences, reissue proceedings and reexaminations) and maintenance of any [ * ] Patent, the matter shall be promptly referred to the [ * ] of Exelixis and [ * ] for BMS. If these two (2) individuals are unable to resolve the
dispute promptly, then the matter shall be promptly elevated to the [ * ] of Exelixis and the [ * ] of BMS. If these two (2) individuals are unable to resolve the dispute promptly, then, subject to Sections 7.7(a)(i)(3), 7.7(a)(i)(4),
7.7(a)(ii), [ * ], and [ * ], [ * ] shall have the final decision, except if such decision: (A) conflicts with the terms of the Agreement; (B) would result in [ * ] described in [ * ] or a [ * ] of the [ * ]; or (C) materially
impacts [ * ] prosecution of Patents that [ * ] a [ * ], in which case of subsection 7.7(a)(i)(2)(A) - (C), [ * ] shall have the final decision. 
 (3) Limitation on Subsection 7.7(a)(i)(2)(B). If [ * ] reasonably believes that filing a new patent application covering a [ * ] (other than the [ * ] of a [ * ]) would result in potential claims [
* ] for [ * ], and if [ * ] disputes with [ * ] that such patent application should be filed, then such dispute shall be discussed as described in the first two (2) sentences of Section 7.7(a)(i)(2), and, if still unresolved, shall
be arbitrated pursuant to Section [ * ], and [ * ] shall not have the right to exercise its final-decision making authority pursuant to Subsection 7.7(a)(i)(2)(B) unless the dispute is resolved in [ * ] favor. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 23 

 (4) Limitation on Subsection 7.7(a)(i)(2)(C). [ * ] hereby covenants that it shall
not, without the prior written consent of [ * ] (which shall not be unreasonably delayed or conditioned), during the term of this Agreement, [ * ] the decision-making authority granted to [ * ] pursuant to Subsection 7.7(a)(i)(2)(C) [ * ]
that is [ * ] as of the Effective Date or [ * ]. Furthermore, if [ * ] the decision-making authority granted to [ * ] pursuant to Subsection 7.7(a)(i)(2)(C) [ * ] by [ * ], [ * ] or [ * ], and such [ * ] is [ * ] or [ * ] a [ * ] that is [ *
], then [ * ] and [ * ] shall agree, pursuant to Section [ * ], on [ * ] the decision-making authority granted to [ * ] pursuant to Subsection 7.7(a)(i)(2)(C). 
 (ii) Abandonment. In no event shall [ * ] knowingly permit any of the [ * ] Patents to be abandoned in any country, or elect not to file a new patent application claiming priority to a patent
application within the [ * ] Patents either before such patent application’s issuance or within the time period required for the filing of an international (i.e., Patent Cooperation Treaty), regional (including European Patent Office) or
national application, without [ * ] written consent (such consent not to be unreasonably withheld, delayed or conditioned) or [ * ] otherwise first being given an opportunity to assume full responsibility (at [ * ] expense) for the continued
prosecution and maintenance of such [ * ] Patents or the filing of such new patent application. Accordingly, [ * ], or [ * ], shall provide [ * ] with notice of the allowance and expected issuance date of any patent within the [ * ] Patents, or any
of the aforementioned filing deadlines, and [ * ] shall provide [ * ] with prompt notice as to whether [ * ] desires [ * ] to file such new patent application. In the event that [ * ] decides either: (A) not to continue the prosecution or
maintenance of a patent application or patent within the [ * ] Patents in any country; or (B) not to file such new patent application requested to be filed by [ * ], [ * ] shall provide [ * ] with notice of this decision at least [ * ] prior to
any pending lapse or abandonment thereof, and [ * ] shall thereafter have the right to assume responsibility for the filing, prosecution and maintenance of such patent or patent application. In the event that [ * ] assumes such responsibility for
such filing, prosecution and maintenance, [ * ] shall no longer have the responsibility for such filing, prosecution and maintenance of such patent applications and patents, and [ * ] shall cooperate as reasonably requested by [ * ] to facilitate
control of such filing, prosecution and maintenance by [ * ]. In the case where [ * ] takes over the filing, prosecution or maintenance of any patent or patent application as set forth above, such patent or patent application shall [ * ] be [ * ]
the [ * ], and [ * ] shall [ * ] such patent or patent application. 
 (iii) Filing, Prosecution and Maintenance of Sole
Invention Patents Controlled by BMS. In accordance with this Section 7.7(a)(iii), BMS shall be responsible for the filing, prosecution (including any interferences, reissues and reexaminations) and maintenance of all Sole Invention
Patents Controlled by BMS. BMS shall provide to Exelixis copies of any papers relating to the filing, prosecution and maintenance of the Sole Invention Patents Controlled by BMS promptly upon their being filed and received. 

(iv) Patent Term Extension. Exelixis and BMS shall each cooperate with each another and shall use commercially reasonable efforts
in obtaining patent term extension (including any pediatric exclusivity extensions as may be available) or supplemental protection certificates or their equivalents in any country with respect to patent rights covering the Products. If elections
with respect to obtaining such patent term extensions are to be made, [ * ] shall have the right to make the election to seek patent term extension or supplemental protection. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 24 

 (v) Exelixis Right to Separate Claims. To the extent that any Sole Invention Patent
of Exelixis contains claims that cover compounds that are not Licensed Compounds (such compounds, “Separable Compounds”), Exelixis shall have the right to separate any claims that cover such Separable Compounds (and not Licensed
Compounds) and to file such claims in a separate application (e.g., a continuation, continuation-in-part, or divisional application). Exelixis shall notify BMS in writing prior to separating such claims, and such separation shall be at
Exelixis’ sole expense. 
 (b) Payment of Prosecution Costs. [ * ] shall bear the out-of-pocket expenses (including
reasonable fees for any outside counsel, [ * ]) associated with the filing, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of: (X) Patents covering [ * ]; and (Y) the [ * ] Patents other
than those [ * ] Patents that are [ * ], provided that if any [ * ] or [ * ] is part of a patent application or patent that is [ * ] but [ * ] that are [ * ], then the Parties shall mutually agree upon an appropriate allocation of the
expenses so that [ * ] does not bear any portion of the out-of-pocket expenses attributable to [ * ]. 
 (c) Payment of
Expenses for Joint Invention Patents. Exelixis and BMS shall mutually agree on the percentage of expenses that each Party shall bear with respect to Joint Invention Patents for which the cost of filing, prosecuting or maintaining such Joint
Invention is not the responsibility of a Party under Section 7.7(b) hereof (which, in the absence of any other agreement between the Parties, shall be divided evenly). 

(d) Non-payment of Expenses. 
 (i) If a Party elects not to pay its share of any expenses with respect to [ * ] Patent in a given country under any of Section [ * ], such Party shall inform the other Party in writing not
less than [ * ] before any relevant deadline (or, in the event of a shorter period in which to respond to a patent office, as soon as reasonably practicable), and, if the other Party assumes the expenses associated with the [ * ] Patent, then the
assuming Party shall thereby become the sole owner of such [ * ] Patent in such country and the other Party shall assign to the assuming Party its rights, title and interests in such [ * ] Patent in such country. 

(ii) If a Party is the assignee or owner of a Patent (other than [ * ]) that is licensed to the other Party under any of
Sections 7.1 or 7.2, and such owning Party elects not to pay its share of expenses pursuant to Section [ * ] in a given country, such owning Party shall inform the other Party in writing not less than [ * ] before any relevant deadline
(or, in the event of a shorter period in which to respond to a patent office, as soon as reasonably practicable). If the other Party assumes the expenses associated with the Patent in such country, then the assuming Party shall thereby [ * ] such
Patent and the owning Party shall [ * ] such Patent in such country. 
 (iii) If a Party is the licensee of a Patent
(other than [ * ]) under any of Sections 7.1 or 7.2, and such Party elects not to pay its share of expenses pursuant to Section [ * ] in a given country, such Party shall inform the other Party in writing not less than [ * ]
before any relevant deadline (or, in the event of a shorter period in which to respond to a patent office, as soon as reasonably practicable) (such Patent(s) in such countries, as identified in such notice, being a “Cost-Terminated Patent
Right”), and shall no longer have any rights under such Sections 7.1 or 7.2, as applicable, with respect to the relevant Patent in such country, provided that all remaining

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 25 

 
rights and licenses under all other Patent(s) within such licensed Patents would remain in effect. It is also understood that such licensee shall be offered the opportunity to assume its share of
the responsibility for the costs of filing, prosecution and maintenance of any Patent(s) claiming priority directly or indirectly from any such Cost-Terminated Patent Right, and that where such expenses are assumed by such licensee, it shall be
afforded all the rights and licenses as provided under this Agreement for the licensed Patents (other than the Cost-Terminated Patent Right) with respect to such Patent(s) claiming priority directly or indirectly from any such Cost-Terminated Patent
Right. 
 (e) Each Party shall provide to the other Party, on [ * ] basis, a patent report that includes the serial
number, docket number and status of each Patent for which such Party has the right to direct the filing, prosecution and maintenance and which [ * ] (in the case of [ * ] such [ * ] that are [ * ]) or [ * ]. The Parties through their patent counsel
shall discuss as appropriate (but not more than [ * ]) ways in which to allocate such out-of-pocket expenses in an appropriate, cost-effective manner consistent with the purposes of this Agreement [ * ]. 

7.8 Enforcement of Patent Rights. 
 (a) Enforcement of Exelixis Sole Patents. 
 (i) Enforcement by [ *
]. In the event that management or in-house counsel for either Party becomes aware of a suspected infringement by a Third Party of a Patent claiming a Sole Invention of Exelixis that claims the composition of matter (including formulation),
manufacture or use of one or more Products that is being Developed or Commercialized by BMS or its Affiliate or sublicensee using Diligent Efforts and which is exclusively licensed to BMS under Section 7.1(c) (for purposes of this
Section 7.8(a)(i) only, an “Exelixis Sole Patent”), such Party shall notify the other Party promptly, and following such notification, the Parties shall confer. Each Party shall provide the same level of disclosure to
the other Party’s in-house counsel concerning suspected infringement of an Exelixis Sole Patent as such Party would provide with respect to suspected infringement of its own issued Patent or an exclusively licensed issued Patent claiming a
product it is developing or commercializing independent of this Agreement. Where such suspected infringement involves such Third Party’s development, manufacture, use or sale of a product directed against ROR, [ * ] shall have the right, but
shall not be obligated, to bring an infringement action against any such Third Party or to defend such proceedings at its own expense, in its own name and entirely under its own direction and control. [ * ] shall reasonably assist [ * ] (at [ * ]
expense) in such actions or proceedings if so requested, and shall lend its name to such actions or proceedings if requested by [ * ] or required by law, and [ * ] shall hold [ * ] harmless from any liability incurred by [ * ] arising out of any
such proceedings or actions at [ * ] request. [ * ] shall have the right to participate and be represented in any such suit by its own counsel at its own expense. No settlement of any such action or defense which restricts the scope, or adversely
affects the enforceability, of any such Exelixis Sole Patent may be entered into by [ * ] without the prior consent of [ * ] (such consent not to be unreasonably withheld, delayed or conditioned). 

(ii) Enforcement by [ * ]. If [ * ] elects not to bring any action for infringement or to defend any proceeding described in
Section 7.8(a)(i) and so notifies [ * ]s, or where [ * ] ([ * ] such Exelixis Sole Patent) otherwise desires to bring an action or to defend any proceeding directly involving an Exelixis Sole Patent, then [ * ] may bring such action or
defend such proceeding at its own expense, in its own name and entirely under its own direction and 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 26 

 
control; provided that [ * ] must confer with [ * ] with respect to any such action or proceeding and obtain the prior written consent of [ * ] to commence such action or proceeding, such
consent not to be unreasonably withheld, delayed or conditioned; provided further, that with respect to any Exelixis Sole Patent that is a Patent [ * ] the [ * ] (or foreign equivalent(s) of such Patent or the [ * ]) by [ * ] (a “[ *
] Patent”), if [ * ] fails to consent to any such action or proceeding, the [ * ] for any [ * ] such Exelixis Sole Patent shall in no event [ * ] by any failure to enforce such Exelixis Sole Patent. [ * ] shall reasonably assist [ *
] (at [ * ] expense) in any action or proceeding being prosecuted or defended by [ * ], if so requested by [ * ] or required by law, and [ * ] shall hold [ * ] harmless from any liability incurred by [ * ] arising out of any such proceedings or
actions. [ * ] shall have the right to participate and be represented in any such suit by its own counsel at its own expense. No settlement of any such action or defense which restricts the scope, or adversely affects the enforceability, of a [ * ]
Patent, may be entered into by [ * ] without the prior consent of [ * ] (such consent not to be unreasonably withheld, delayed or conditioned). 
 (b) Enforcement of Joint Invention Patents. 
 (i) Joint Product
Patents. 
 (1) Enforcement by [ * ]. In the event that management or in-house counsel for either Party becomes aware
of a suspected infringement of a Patent claiming a Joint Invention that pertains to the composition of matter (including formulation), manufacture or use of one or more Products that is being developed or commercialized by BMS or its Affiliate or
sublicensee using Diligent Efforts and which is exclusively licensed to BMS under Section 7.1(c) (a “Joint Product Patent”), such Party shall notify the other Party promptly, and following such notification, the Parties
shall confer. Each Party shall provide the same level of disclosure to the other Party’s in-house counsel concerning suspected infringement of a Joint Product Patent as such Party would provide with respect to suspected infringement of its own
issued Patent or an exclusively licensed issued Patent claiming a product it is developing or commercializing independent of this Agreement. [ * ] shall have the right, but shall not be obligated, to bring an infringement action or to defend such
proceedings at its own expense, in its own name and entirely under its own direction and control. [ * ] shall reasonably assist [ * ] (at [ * ] expense) in such actions or proceedings if so requested, and shall lend its name to such actions or
proceedings if requested by [ * ] or required by law, and [ * ] shall hold [ * ] harmless from any liability incurred by [ * ] arising out of any such proceedings or actions. [ * ] shall have the right to participate and be represented in any such
suit by its own counsel at its own expense. No settlement of any such action or defense which restricts the scope or affects the enforceability of a Joint Product Patent may be entered into by [ * ] without the prior consent of [ * ] (such consent
not to be unreasonably withheld, delayed or conditioned). 
 (2) Enforcement by [ * ]. If [ * ] elects not to bring any
action for infringement or to defend any proceeding described in Section 7.8(b)(i)(1) and so notifies [ * ]s, or for any other enforcement by [ * ] of a Joint Product Patent which is exclusively licensed to BMS under
Section 7.1(c), then [ * ] may bring such action or defend such proceeding at its own expense, in its own name and entirely under its own direction and control; provided that [ * ] must confer with [ * ] with respect to any such
action or proceeding and obtain the prior written consent of [ * ] to commence such action or proceeding, such consent not to be unreasonably withheld, delayed or conditioned; provided further, that with respect to any Joint Product Patent
that is a [ * ] Patent, if [ 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 27 

 
* ] fails to consent to any such action or proceeding, the [ * ] for any [ * ] such Joint Product Patent shall in no event [ * ] by any failure to enforce such Joint Product Patent. [ * ]
shall reasonably assist [ * ] (at [ * ] expense) in any action or proceeding being prosecuted or defended by [ * ], if so requested by [ * ] or required by law, and [ * ] shall hold [ * ] harmless from any liability incurred by [ * ] arising out of
any such proceedings or actions. [ * ] shall have the right to participate and be represented in any such suit by its own counsel at its own expense. No settlement of any such action or defense which restricts the scope or affects the enforceability
of a Joint Product Patent may be entered into by [ * ] without the prior consent of [ * ] (such consent not to be unreasonably withheld, delayed or conditioned). 
 (ii) Other Joint Patents. 
 (1) Enforcement by [ * ]. In the event
that management or in-house counsel for either Party becomes aware of a suspected infringement of a Patent that claims a Joint Invention but is not a Joint Product Patent (an “Other Joint Patent”), such Party shall notify the other
Party promptly, and following such notification, the Parties shall confer. Each Party shall provide the same level of disclosure to the other Party’s in-house counsel concerning suspected infringement of an Other Joint Patent as such Party
would provide with respect to suspected infringement of its own issued Patent or an exclusively licensed issued Patent claiming a product it is developing or commercializing independent of this Agreement. [ * ] shall have the right, but shall not be
obligated, to prosecute an infringement action or to defend such proceedings at its own expense, in its own name and entirely under its own direction and control. [ * ] shall reasonably assist [ * ] (at [ * ] expense) in such actions or proceedings
if so requested, and shall lend its name to such actions or proceedings if requested by [ * ] or required by law, and [ * ] shall hold [ * ] harmless from any liability incurred by [ * ] arising out of any such proceedings or actions. [ * ] shall
have the right to participate and be represented in any such suit by its own counsel at its own expense. No settlement of any such action or defense which restricts the scope or affects the enforceability of an Other Joint Patent may be entered into
by [ * ] without the prior consent of [ * ] (such consent not to be unreasonably withheld, delayed or conditioned). 
 (2)
Enforcement by [ * ]. If [ * ] elects not to bring any action for infringement or to defend any proceeding described in Section 7.8(b)(ii)(1) and so notifies [ * ], then [ * ] may bring such action or defend such proceeding at its
own expense, in its own name and entirely under its own direction and control; provided that [ * ] must confer with [ * ] with respect to any such action or proceeding and obtain the prior written consent of [ * ] to commence such action or
proceeding, such consent not to be unreasonably withheld, delayed or conditioned; provided further, that with respect to any Other Joint Patent that is a [ * ] Patent, if [ * ] fails to consent to any such action or proceeding, the [ * ] for
any [ * ] such Other Joint Patent shall in no event [ * ] by any failure to enforce such Other Joint Patent. [ * ] shall reasonably assist [ * ] (at [ * ] expense) in any action or proceeding being prosecuted or defended by [ * ], if so requested by
[ * ] or required by law, and [ * ] shall hold [ * ] harmless from any liability incurred by [ * ] arising out of any such proceedings or actions. [ * ] shall have the right to participate and be represented in any such suit by its own counsel at
its own expense. No settlement of any such action or defense which restricts the scope or affects the enforceability of an Other Joint Patent may be entered into by [ * ] without the prior consent of [ * ] (such consent not to be unreasonably
withheld, delayed or conditioned). 
 (c) General Provisions Relating to Enforcement of Patents. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 28 

 (i) Withdrawal. If either Party brings such an action or defends such a proceeding
under this Section 7.8 and subsequently ceases to pursue or withdraws from such action or proceeding, it shall promptly notify the other Party and the other Party may substitute itself for the withdrawing Party under the terms of this
Section 7.8 (including such prior written consent as provided for under this Section 7.8) at its own expense; provided, however, that [ * ] right to substitute itself for [ * ] pursuant to this Section 7.8(c)(i)
shall be limited, with respect to [ * ] Patents, to actions and proceedings that [ * ] initially had the first right to bring or defend pursuant to Section [ * ]. 
 (ii) Recoveries. In the event either Party exercises the rights conferred in this Section 7.8 and recovers any damages or other sums in such action, suit or proceeding or in settlement
thereof, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by the Parties in connection therewith, including attorneys fees. If such recovery is insufficient to cover all such costs and
expenses of both Parties, it shall be shared in proportion to the total such costs and expenses incurred by each Party. If after such reimbursement any funds shall remain from such damages or other sums recovered, such funds shall be [ * ].

 (d) Data Exclusivity and Orange Book Listings. With respect to data exclusivity periods (such as those periods listed
in the FDA’s Orange Book (including any available pediatric extensions) or periods under national implementations of Article 9.1(a)(iii) of Directive 2001/EC/83, and all international equivalents), BMS shall use commercially reasonable efforts
consistent with its obligations under applicable law (including any applicable consent order) to seek, maintain and enforce all such data exclusivity periods available for the Products. With respect to filings in the FDA Orange Book (and foreign
equivalents) for issued patents for a Product, upon request by BMS (and at BMS’ expense), Exelixis shall provide reasonable cooperation to BMS in filing and maintaining such Orange Book (and foreign equivalent) listings. 

(e) No Action in Violation of Law. Neither Party shall be required to take any action pursuant to this Section 7.8
that such Party reasonably determines in its sole judgment and discretion conflicts with or violates any court or government order or decree applicable to such Party. 
 (f) Notification of Patent Certification. [ * ] shall notify and provide [ * ] with copies of any allegations of alleged patent invalidity, unenforceability or non-infringement of any [ * ] Patent
[ * ] hereunder pursuant to a Paragraph IV Patent Certification by a Third Party filing an Abbreviated New Drug Application, an application under §505(b)(2) or other similar patent certification by a Third Party, and any foreign equivalent
thereof. Such notification and copies shall be provided to [ * ] by [ * ] as soon as practicable and at least within [ * ] after [ * ] receives such certification, and shall be sent by facsimile and overnight courier to the address set forth below:

 [ * ] 
 7.9 Defense of Third Party Claims. If a claim is brought by a Third Party that any activity related to work performed by a Party under the Agreement infringes the intellectual property rights of
such Third Party, each Party shall give prompt written notice to the other Party of such claim, and following such notification, the Parties shall confer on how to respond. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 29 

	8.	COMPENSATION 

 8.1
Upfront Payment. BMS shall pay Exelixis an upfront payment of Five Million Dollars ($5,000,000) on the earlier to occur of the following: (a) [ * ] after the Effective Date; or (b) [ * ] after the Effective Date (as defined in the TGR5
License Agreement). Such payment shall be noncreditable and nonrefundable. 
 8.2 Milestone Payments to Exelixis.

 (a) Development and Regulatory Milestones. 

(i) BMS shall make the milestone payments set forth below to Exelixis within [ * ] after the first achievement of each indicated
event by BMS or any of its Affiliates or sublicensees and, subject to Section 8.2(a)(iii), with respect to each of the events described in [ * ] below, after the first achievement of each such event with respect to any Licensed Compound.
For clarity, with respect to milestones that are triggered by the [ * ], such [ * ] must be [ * ] that is [ * ] and [ * ] the [ * ] or [ * ] of the [ * ]. All such milestone payments made by BMS to Exelixis hereunder shall be noncreditable and
nonrefundable. 
  

			
	 Event
	  	 Milestone Payment

	(1) [ * ]	  	$[ * ]
	(2) [ * ]	  	$[ * ]
	(3) [ * ]	  	$[ * ]
	(4) [ * ]	  	$[ * ]
	(5) [ * ]	  	$[ * ]
	(6) [ * ]	  	$[ * ]
	(7) [ * ]	  	$[ * ]
	(8) [ * ]	  	$[ * ]
	(9) [ * ]	  	$[ * ]
	(10) [ * ]	  	$[ * ]
	(11) [ * ]	  	$[ * ]
	(12) [ * ]	  	$[ * ]
	(13) [ * ]	  	$[ * ]
	(14) [ * ]	  	$[ * ]

 (ii) Milestone
Payment Restrictions. Each milestone payment set forth in Section 8.2(a)(i) shall be paid [ * ] with respect to [ * ], [ * ] the [ * ] or [ * ] the[ * ] in [ * ] for [ * ], or the [ * ] or [ * ] for [ * ]. 

(iii) Milestone Payments for [ * ]. If BMS is diligently developing and paying milestones to Exelixis under
Section 8.2(a)(i) [ * ], the payments [ * ] made to Exelixis under Sections 8.2(a)(i) for [ * ] shall be [ * ] such [ * ] the [ * ] in [ * ], in which case BMS shall pay Exelixis the [ * ] the [ * ] in [ * ] within [ * ] of the [
* ] such [ * ]; provided, however, that if this Agreement terminates before such [ * ], then BMS shall [ * ] pay Exelixis the [ * ]. If [ * ] the [ * ] or [ * ], then BMS shall only pay milestones [ * ] for the events that [ * ] the [ * ] such [ *
]; 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 30 

 
however, if a [ * ], then BMS shall pay the milestones [ * ] a [ * ] have been paid [ * ]. For clarity, the Parties agree that [ * ] shall [ * ], [ * ], or [ * ] of the [ * ] the [ * ].

 (b) Commercial Milestones. BMS shall make the milestone payments set forth below to Exelixis after first achievement
of each indicated event by BMS or any of its Affiliates or sublicensees with respect to each Product. Each milestone payment shall be made by BMS [ * ], [ * ] due and payable [ * ] after the end of the [ * ] in which such milestone event is met. BMS
shall pay [ * ] to Exelixis [ * ] if, at the time [ * ], the [ * ] the payment obligation (the “[ * ]”) was [ * ] for the [ * ]. Otherwise, the [ * ] shall be [ * ], provided that [ * ]. BMS shall pay [ * ] to Exelixis [ * ] if, at
the time [ * ], the [ * ] for the [ * ]. Otherwise, the [ * ] shall be [ * ], provided that [ * ]. All such milestone payments made by BMS to Exelixis hereunder shall be noncreditable and nonrefundable, and shall be paid only once with respect to
each Product, regardless of [ * ] or [ * ] for that Product, or [ * ] or [ * ] for that Product. 
  

			
	 Event
	  	 Milestone Payment

	[ * ]	  	$[ * ]
	[ * ]	  	$[ * ]
	[ * ]	  	$[ * ]

 8.3 Royalty
Payments to Exelixis for Net Sales of Products. For each Product, BMS shall pay to Exelixis royalties on Net Sales of such Product by BMS (or its Affiliates or sublicensees) in the Territory at a royalty rate determined by aggregate Net Sales in
the Territory of such Product in a calendar year as follows: 
  

					
	 Calendar year Net Sales of Products
	  	Royalty Rate for
Products Comprising
an Exelixis ROR
Compound	 	Royalty Rate for
Products Not
Comprising an Exelixis
ROR Compound
	 First $[ * ]
	  	[ * ]%	 	[ * ]%
	 Portion above $[ * ] and up to and including $[ * ]
	  	[ * ]%	 	[ * ]%
	 Portion above $[ * ]
	  	[ * ]%	 	[ * ]%

 For clarity, Net
Sales shall be [ * ]. For the purpose of this Section 8.3, all Products [ * ] shall be [ * ] and the Net Sales of such Products shall be [ * ] the [ * ], regardless of whether [ * ] or [ * ], or [ * ] or [ * ]. All royalty payments made
by BMS to Exelixis hereunder shall be noncreditable and nonrefundable, [ * ] royalties to Exelixis, in which case such [ * ] shall be [ * ] (or, in the event that [ * ], such [ * ] shall be [ * ]). 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 31 

 8.4 Third Party Royalties 

(a) [ * ] all Third Party royalties owed with respect to a Product in the Territory on intellectual property that is intellectual
property that: (A) [ * ] from a Third Party prior to the Effective Date and [ * ]; and (B) [ * ]. Subject to Section 8.4(b), [ * ] Third Party royalties owed on intellectual property in connection with the development and
commercialization of a Product in the Territory; provided that each Party shall bear all Third Party royalties arising from any infringing activities by such Party prior to the Effective Date. 

(b) BMS may deduct from the royalties it would otherwise owe to Exelixis pursuant to Section 8.3 for a particular
Product, an amount equal to [ * ] of all royalties payable to a Third Party in consideration for rights necessary or reasonably useful for the manufacture, use or sale of such Product, up to a maximum deduction of [ * ] of the royalties due Exelixis
for such Product. 
 8.5 [ * ]. During the applicable Royalty Term for a particular Product, if the Patents claiming the
composition of matter of such Product have expired, and if any [ * ]: (a) [ * ] in any given country in any year; and (b) such [ * ] in such country for such year are, [ * ]: 

(i) [ * ], but [ * ] of the [ * ] in such country, then [ * ]; or 

(ii) [ * ] of the [ * ] in such country, then [ * ]. 
 8.6 Limitation on Deductions. Notwithstanding anything to the contrary in this Agreement, the operation of Sections 8.4 and 8.5 for a given Product, whether singularly or in
combination with each other, shall not [ * ]. 
 8.7 Quarterly Payments and Reports. All royalties due under
Section 8.3 shall be paid quarterly, on a country-by-country basis, within [ * ] of the end of the relevant quarter for which royalties are due. BMS shall provide to Exelixis within [ * ] after the end of each quarter a report that
summarizes the Net Sales of a Product during such quarter, provided that to the extent additional information is reasonably required by Exelixis to comply with its obligations to any of its licensors, the Parties shall work together in good
faith to timely compile and produce such additional information. Such reports shall also include detailed information regarding the calculation of royalties due pursuant to Section 8.3, including allowable deductions in the
calculation of Net Sales of each Product on which royalties are paid, and, to the extent Section 8.5 is applicable, the calculation of [ * ] and [ * ] of [ * ]. 
 8.8 Term of Royalties. Exelixis’ right to receive royalties under Section 8.3 shall expire on a country-by-country and Product-by-Product basis upon the later of: (a) [ * ];
or (b) [ * ] (the “Royalty Term”). Upon the expiration of the Royalty Term with respect to a Product in a country, BMS shall have a fully-paid-up perpetual license under Section 7.1(c) for the making, using,
selling, offering for sale and importing of such Product in such country. 
 8.9 Payment Method. All payments due under
this Agreement to Exelixis shall be made by bank wire transfer in immediately available funds to an account designated by Exelixis. All payments hereunder shall be made in Dollars. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 32 

 8.10 Taxes. Exelixis shall pay any and all taxes levied on account of all payments it
receives under this Agreement. If laws or regulations require that taxes be withheld, BMS shall: (a) deduct those taxes from the remittable payment; (b) pay the taxes to the proper taxing authority; and (c) send evidence of the
obligation together with proof of tax payment to Exelixis within [ * ] following that tax payment. The Parties shall discuss appropriate mechanisms for minimizing such taxes to the extent possible in compliance with applicable law. 

8.11 Blocked Currency. In each country where the local currency is blocked and cannot be removed from the country, royalties
accrued in that country shall be paid to Exelixis in Dollars based on the Dollar reported sales for the quarter (translated for such country per Statement of Financial Standards No. 52), unless otherwise mutually agreed. 

8.12 Sublicenses. In the event BMS grants any permitted licenses or sublicenses to Third Parties to sell Products that are
subject to royalty payments under Section 8.3, BMS shall have the responsibility to account for and report sales of any Product by a licensee or a sublicensee on the same basis as if such sales were Net Sales by BMS. BMS shall pay
to Exelixis (or cause the licensee or sublicensee to pay to Exelixis, with BMS remaining responsible for any failure of the licensee or sublicensee to pay amounts when due under this Agreement): (a) royalties on such sales as if such sales of
the licensee or sublicensee were Net Sales of BMS or any of its Affiliates; and (b) milestones payments pursuant to Section 8.2 based on the achievement by such licensee or sublicensee of any milestone event contemplated in such
Sections as if such milestone event had been achieved by BMS or any of its Affiliates hereunder. Any sales by BMS’ Affiliates and sublicensees of BMS or such sublicensee’s Affiliates, in each case to Third Parties, shall be aggregated with
sales by BMS for the purpose of calculating the aggregate Net Sales in Sections 8.2(b) and 8.3. 
 8.13 Foreign
Exchange. Conversion of sales recorded in local currencies to Dollars shall be performed in a manner consistent with BMS’ normal practices used to prepare its audited financial statements for internal and external reporting purposes, which
uses a widely accepted source of published exchange rates. 
 8.14 Records. BMS shall keep (and shall ensure that its
Affiliates and sublicensees shall keep) such records as are required to determine, in a manner consistent with GAAP and this Agreement, the sums due under this Agreement, including Net Sales. All such books, records and accounts shall be retained by
BMS until the later of (a) [ * ] after the end of the period to which such books, records and accounts pertain and (b) the [ * ] (or any extensions thereof), or for such longer period as may be required by applicable law. BMS shall require
its sublicensees to provide to it a report detailing the foregoing expenses and calculations incurred or made by such sublicensee, which report shall be made available to Exelixis in connection with any audit conducted by Exelixis pursuant to
Section 8.15. 
 8.15 Audits. Exelixis shall have the right to have an independent certified public
accountant, reasonably acceptable to BMS, to have access during normal business hours, and upon reasonable prior written notice, to examine only those records of BMS (and its Affiliates and sublicensees) as may be reasonably necessary to determine,
with respect to any calendar year ending not more than [ * ] prior to Exelixis’ request, the correctness or completeness of any report or payment made under this Agreement. The foregoing right of review may be exercised [ * ].

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 33 

 
Results of any such examination shall be: (a) limited to information relating to the Products; (b) made available to both Parties; and (c) subject to Article 10. Exelixis
shall bear the full cost of the performance of any such audit, unless such audit discloses a variance to the detriment of Exelixis of more than [ * ] from the amount of the original report, royalty or payment calculation, in which case BMS shall
bear the full cost of the performance of such audit. The results of such audit shall be [ * ]. 
 8.16 Interest. Any
payments or portions thereof due hereunder that are not paid on the date such payments are due under this Agreement shall bear interest at a rate equal to the lesser of: (a) [ * ] Rate as published by Citibank, N.A., New York, New York, or any
successor thereto, at 12:01 a.m. on the first day of each quarter in which such payments are overdue; or (b) the maximum rate permitted by law, in each case calculated on the number of days such payment is delinquent, compounded monthly.

 8.17 Non-Monetary Consideration. In the event that BMS or its Affiliate or sublicensee receives any non-monetary
consideration in connection with the sale of a Product, BMS’ payment obligations under this Article 8 shall be based on the fair market value of such other consideration. In such case, BMS shall disclose the terms of such
arrangement to Exelixis and the Parties shall endeavor in good faith to agree on such fair market value. 
 8.18 Payments to
or Reports by Affiliates. Any payment required under any provision of this Agreement to be made to either Party or any report required to be made by any Party shall be made to or by an Affiliate of that Party if designated in writing by
that Party as the appropriate recipient or reporting entity. 
  

	9.	EXCLUSIVITY 

 9.1
Licensed Compounds. This Agreement will be exclusive with respect to the Development, Manufacture, and Commercialization of [ * ] that are intended to [ * ] as described below [ * ]. 

(a) Prior to Commercialization. Subject to Sections 9.2, 9.3 and 9.4, [ * ], [ * ] (directly or indirectly, and
either with or without a bona fide collaborator) outside the scope of this Agreement any programs: (i) that [ * ] that [ * ]; or (ii) where [ * ]. 
 (b) Subsequent to Commercialization. Subject to Sections 9.2, 9.3 and 9.4, [ * ], [ * ] (directly or indirectly, and either with or without a bona fide collaborator) outside
the scope of this Agreement any programs to [ * ] that [ * ], and any [ * ] subject to the following terms and conditions: 

(i) Commercial Launch of [ * ]. [ * ], any product [ * ]: (A) that is [ * ] and [ * ]; or (B) where the [ * ] that [ *
] (any such product, a “[ * ]”), for a [ * ] of a [ * ]. 
 (ii) [ * ] of a [ * ]. In the event of any [ * ]
of a [ * ] that is permitted under Section [ * ], the Party [ * ] shall [ * ] a [ * ]: [ * ] of any [ * ] for a [ * ] subsequent to [ * ] of a [ * ] and [ * ] the [ * ] the [ * ] with respect to such [ * ] or [ * ] of this Agreement (in either case,
[ * ]). 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 34 

 9.2 [ * ]. Notwithstanding anything to the contrary set forth in this Article
9, if a Party is engaged in [ * ] a program that is [ * ] that is [ * ], and [ * ] such program [ * ], such Party shall [ * ] with such [ * ] in order to [ * ] so the [ * ] the [ * ] for [ * ]. 

9.3 Not Applicable to [ * ] or [ * ]. The restrictions and obligations in Section 9.1 shall not apply with respect to
either Party for [ * ] that are [ * ] by such Party [ * ] (either with or without a bona fide collaborator) or for any [ * ]. 
 9.4 [ * ] Right. [ * ] may [ * ] with a [ * ] that [ * ] a [ * ] solely with respect to the [ * ] of [ * ] and/or a [ * ] that [ * ]: (a) any [ * ] product that is [ * ] a [ * ]; and
(b) such [ * ] a [ * ], on the condition that [ * ] to [ * ] of [ * ] with respect to [ * ] as set forth herein (assuming such [ * ] and/or a [ * ]). 
  

	10.	CONFIDENTIALITY 

 10.1
Nondisclosure of Confidential Information. All Information or Materials disclosed by one Party to the other Party pursuant to this Agreement, and, subject to Section 10.6, Information that is generated pursuant to this Agreement with
respect to Licensed Compounds or Products (for so long as such Licensed Compound or Product is not removed from the Agreement as a result of a Product specific termination pursuant to Section 11.3), shall be “Confidential
Information” for all purposes hereunder. The Parties agree that, during term of this Agreement and for a period of [ * ] thereafter, a Party receiving Confidential Information of the other Party shall: (a) use Diligent Efforts to
maintain in confidence such Confidential Information (but not less than those efforts as such Party uses to maintain in confidence its own proprietary industrial information of similar kind and value) and not to disclose such Confidential
Information to any Third Party without prior written consent of the other Party (such consent not to be unreasonably withheld, delayed or conditioned), except for disclosures made in confidence to any Third Party under terms consistent with this
Agreement and made in furtherance of this Agreement or of rights granted to a Party hereunder; and (b) not use such other Party’s Confidential Information for any purpose except those permitted by this Agreement (it being understood that
this Section 10.1 shall not create or imply any rights or licenses not expressly granted under Article 4, 7 or 11 hereof). 
 10.2 Exceptions. The obligations in Section 10.1 shall not apply with respect to any portion of the Confidential Information that the receiving Party can show by competent written
proof: 
 (a) Is publicly disclosed by the disclosing Party, either before or after it is disclosed to the receiving Party
hereunder; or 
 (b) Was known to the receiving Party or any of its Affiliates, without obligation to keep it
confidential, prior to disclosure by the disclosing Party; or 
 (c) Is subsequently disclosed to the receiving Party or
any of its Affiliates by a Third Party lawfully in possession thereof and without obligation to keep it confidential; or 

(d) Is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it
is disclosed to the receiving Party, and is not 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 35 

 
directly or indirectly supplied by the receiving Party in violation of this Agreement; or 
 (e) Has been independently developed by employees or contractors of the receiving Party or any of its Affiliates without the aid, application or use of the disclosing Party’s Confidential
Information. 
 10.3 Authorized Disclosure. A Party may disclose the Confidential Information belonging to the other
Party to the extent such disclosure is reasonably necessary in the following instances; provided that notice of any such disclosure shall be provided as soon as practicable to the other Party: 

(a) Filing or prosecuting Patents relating to Sole Inventions, Joint Inventions or Products, in each case pursuant to activities
under this Agreement; 
 (b) Regulatory filings; 

(c) Prosecuting or defending litigation; 
 (d) Complying with applicable governmental laws and regulations; and 

(e) Disclosure, in connection with the performance of this Agreement, or exercise of its rights hereunder, to Affiliates,
potential collaborators, partners, and actual and potential licensees (including potential co-marketing and co-promotion contractors, research contractors and manufacturing contractors), research collaborators, potential investment bankers,
investors, lenders, and investors, employees, consultants, or agents, each of whom prior to disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 10.

 The Parties acknowledge that the terms of this Agreement shall be treated as Confidential Information of both Parties. Such terms may be
disclosed by a Party to individuals or entities covered by Section 10.3(e) above, each of whom prior to disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent in scope to those set forth in
this Article 10. In addition, a copy of this Agreement may be filed by either Party with the Securities and Exchange Commission in connection with any public offering of such Party’s securities, in connection with such Party’s
on-going periodic reporting requirements under the federal securities laws, or as otherwise necessary under applicable law or regulations. In connection with any such filing, such Party shall endeavor to obtain confidential treatment of economic,
competitively sensitive, and trade secret information. 
 10.4 Prior Confidentiality Agreement. All Information exchanged
between the Parties under the Confidential Disclosure Agreement between Exelixis and BMS executed as of [ * ], and amended as of [ * ] and [ * ] (such confidential disclosure agreement, as amended, the “Prior CDA”) that relates to
ROR, ROR Antagonists, [ * ] and [ * ] ROR Antagonists, Licensed Compounds or Products shall be deemed Confidential Information and shall, commencing upon the Effective Date, be subject to the terms of this Article 10 rather than the Prior
CDA. The Prior CDA shall otherwise remain in full force and effect, including with respect to each Party’s rights with respect to breaches thereof, if any, that occurred prior to the Effective Date with respect to

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 36 

 
Information described in the first sentence of this Section 10.4. 
 10.5 Publicity. The Parties agree that the public announcement of the execution of this Agreement shall be substantially in the form of the press release attached as Exhibit 10.5. Any other
publication, news release or other public announcement relating to this Agreement or to the performance hereunder, shall first be reviewed and approved by both Parties; provided, however, that any disclosure which is required by law,
including disclosures required by the U.S. Securities and Exchange Commission or made pursuant to the requirements of the national securities exchange or other stock market on which such Party’s securities are traded, as advised by the
disclosing Party’s counsel may be made without the prior consent of the other Party, although the other Party shall be given prompt notice of any such legally required disclosure and to the extent practicable shall provide the other Party an
opportunity to comment on the proposed disclosure. 
 10.6 Publications. Subject to Section 10.3, each Party
agrees to provide the other Party the opportunity to review any proposed disclosure which contains Confidential Information of the other Party and would or may constitute an oral, written or electronic public disclosure if made (including the full
content of proposed abstracts, manuscripts or presentations) which relate to any Inventions, at least [ * ] prior to its intended submission for publication and agrees, upon request, not to submit any such abstract or manuscript for publication
until the other Party is given a reasonable period of time to secure patent protection for any material in such publication which it believes to be patentable; provided, however, that BMS may publish results of clinical studies relating to
Licensed Compounds without the prior review or approval of Exelixis. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications. The Parties agree to review and
consider delay of publication and filing of patent applications under certain circumstances. The Alliance Managers (or the Parties), as appropriate, shall review such requests and recommend subsequent action. Subject to Section 10.3,
neither Party shall have the right to publish or present Confidential Information of the other Party which is subject to Section 10.1. Nothing contained in this Section 10.6 shall prohibit the inclusion of Confidential
Information of the non-filing Party necessary for a patent application, provided the non-filing Party is given a reasonable opportunity to review the extent and necessity for its Confidential Information to be included prior to submission of
such patent application related to the Agreement. Any disputes between the Parties regarding delaying a publication or presentation to permit the filing of a patent application shall be referred to the Alliance Managers (or the Parties), as
appropriate. 
  

	11.	TERM AND TERMINATION 

11.1 Term. This Agreement shall become effective on the Effective Date and shall remain in effect, subject to earlier termination
in accordance with Sections 11.2 or 11.3 or by mutual written agreement, until the expiration of all payment obligations under Article 8 (the “Term”). 

11.2 BMS’ Right to Terminate. BMS shall have the right to terminate this Agreement, at any time, [ * ]: (a) [ * ] prior
written notice to Exelixis, in the event that such termination is [ * ] of the [ * ]; or (b) [ * ] prior written notice to Exelixis, in the event that such termination is [ * ] of the [ * ]. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 37 

 11.3 Termination for Material Breach or Patent Challenge 

(a) Notice. If either Party believes that the other is in material breach of this Agreement (including any material breach of a
representation or warranty made in this Agreement), then the non-breaching Party may deliver notice of such breach to the other Party. In such notice the non-breaching Party shall identify the actions or conduct that such Party would consider to be
an acceptable cure of such breach. For all breaches other than a failure to make a payment set forth in Article 8, the allegedly breaching Party shall have [ * ] to cure such breach. For any breach arising from a failure to make a payment set
forth in Article 8, the allegedly breaching Party shall have [ * ] to cure such breach. 
 (b) Cure Period.
Subject to Section 11.3(c), if the Party receiving notice of breach fails to cure such breach within the [ * ] period or [ * ] period (as applicable), or the Party providing the notice reasonably determines that the proposed corrective
plan or the actions being taken to carry it out is not commercially practicable, the Party originally delivering the notice may terminate this Agreement upon [ * ] advance written notice, provided, that if the breach [ * ] or [ * ], the
non-breaching Party may [ * ] the [ * ] with respect to [ * ]. 
 (c) [ * ] Material Breach. If a Party gives notice of
termination under Section 11.3(a) and the other Party [ * ], or if a Party determines under Section 11.3(b) that the [ * ] or the [ * ] is [ * ] and such [ * ] such [ * ], then the [ * ]: (i) [ * ]; or (ii) [ * ] or
the [ * ], shall in any case [ * ]. If [ * ] of such [ * ] it is [ * ] the [ * ], then such termination shall [ * ] if the breaching Party fails [ * ] to cure such breach in accordance with the [ * ] within the time period set forth in
Section 11.3(a) for the applicable breach [ * ]. If [ * ] of such [ * ] it is [ * ] the [ * ], then [ * ] and [ * ]. 
 (d) Termination for Patent Challenge. Exelixis may terminate this Agreement with respect to a given Product in a given country if BMS or its Affiliates or sublicensees, directly or indirectly,
individually or in association with any other person or entity, challenge the validity, enforceability or scope of any Exelixis Licensed Patents that relate to such Product in such country; provided that, if BMS, due to a Change of Control
transaction, acquires control of a company that is challenging, directly or indirectly, individually or in association with another person or entity, the validity, enforceability or scope of any Exelixis Licensed Patents, BMS shall have [ * ] from
the date of such acquisition to terminate such challenge to such Exelixis Licensed Patents before Exelixis’ right to terminate under this Section 11.3(d) becomes effective. For clarity, any dispute as to whether a given Patent is
within the scope of Exelixis Licensed Patents, such matter shall be subject to dispute resolution as set forth in Section 14.3. 
 11.4 Survival; Effect of Termination. 
 (a) In the event of
expiration or termination of this Agreement, the following provisions of this Agreement shall survive: Articles [ * ]; and Sections [ * ] (with respect to [ * ] (and [ * ] for such purposes)); the last sentence of Section [ * ] with
respect to [ * ] in the event of expiration of this Agreement pursuant to Section [ * ] and with respect to [ * ] in the event of termination of this Agreement [ * ], [ * ]. 

(b) Notwithstanding anything to the contrary in this Agreement, in the event of termination of this Agreement pursuant to
Section [ * ], [ * ] under this Agreement [ * ] of the [ * ] 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 38 

 
shall [ * ]. In such case, the non-breaching Party shall continue to hold the licenses granted hereunder, subject to the milestone and royalties set forth herein (which relevant provisions shall
survive termination). 
 (c) In any event, expiration or termination of this Agreement shall not relieve the Parties of
any liability which accrued hereunder prior to the effective date of such expiration or termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this
Agreement nor prejudice either Party’s right to obtain performance of any obligation. 
 11.5 Licenses and Payments on
Expiration or Termination. 
 (a) Research, Development and Commercialization of Reverted Compounds by Exelixis.

 (i) Upon termination of this Agreement (other than for Exelixis’ uncured material breach pursuant to
Section 11.3), subject to Section 11.5(b), BMS hereby grants Exelixis a worldwide, royalty-bearing (solely to the extent provided in the Reverted Compounds License Agreement) license (with the right to sublicense) to
clinically develop, make, have made, use, import, sell, offer to sell and have sold products incorporating any Reverted Compounds that are described in Section 1.55(a), under any Information and Patents Controlled by BMS that
(A) cover one (1) or more of such Reverted Compounds, and/or any composition containing any of the foregoing, or the manufacture or use thereof or (B) are [ * ] to clinically develop, make, have made, use, import, sell, offer to sell
and have sold Products incorporating any such Reverted Compound. The license described in this Section 11.5(a)(i) shall be [ * ] for [ * ] and [ * ] for [ * ]. 
 (ii) Upon expiration of this Agreement pursuant to Section 11.1 or termination of this Agreement, subject to Section 11.5(b) and Section 11.6, BMS hereby grants
Exelixis a worldwide, royalty-free license (with the right to sublicense) to clinically develop, make, have made, use, import, sell, offer to sell and have sold products incorporating any Reverted Compounds that are described in
Section 1.55(b), under any Information and Patents Controlled by BMS that (A) cover one (1) or more of such Reverted Compounds, and/or any composition containing any of the foregoing, or the manufacture or use thereof or
(B) are [ * ] to clinically develop, make, have made, use, import, sell, offer to sell and have sold Products incorporating any such Reverted Compound. The license described in this Section 11.5(a)(ii) shall be [ * ] for [ * ] and [
* ] for [ * ]. 
 (iii) Upon termination of this Agreement, subject to Section 11.5(b) and
Section 11.6, BMS hereby grants Exelixis a worldwide, royalty-free license (without the right to sublicense except to Third Party contract research providers and manufacturers) to research, identify, derivatize, pre-clinically develop,
make, have made and use Licensed Compounds for research purposes, under any BMS Licensed Know-How and BMS Licensed Patents covering one (1) or more Licensed Compounds, and/or any composition containing any of the foregoing, or the manufacture
or use thereof. The license described in this Section 11.5(a)(iii) shall be: (A) [ * ] with respect to [ * ]; (B) [ * ] for [ * ]; and (C) [ * ] for [ * ]. Notwithstanding anything to the contrary in this Agreement, the
foregoing license grant shall not create (by any means, whether expressly, impliedly or by estoppel) any right or license under any other Patents, Information or other 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 39 

 
intellectual property right that is Controlled by BMS. 
 (iv)
Upon termination of this Agreement, subject to Section 11.5(b) and Section 11.6, BMS hereby grants Exelixis a [ * ], worldwide, royalty-free license (without the right to sublicense except to Third Party contract research
providers and manufacturers) to research, identify, derivatize, pre-clinically develop, make, have made and use Licensed Compounds for research purposes, under any Information or Patents Controlled by BMS that are [ * ] for the research,
identification, derivatization, pre-clinical development, making, having made and use of Licensed Compounds in a manner consistent with the activities performed by (A) the Parties under the Research Plan or (B) BMS pursuant to the BMS
Independent Program. Notwithstanding anything to the contrary in this Agreement, the foregoing license grant shall not create (by any means, whether expressly, impliedly or by estoppel) any right or license under any other Patents, Information or
other intellectual property right that is Controlled by BMS. 
 (v) Upon termination of this Agreement, BMS shall
transfer via assignment, license or sublicense to Exelixis: (A) all Information reasonably necessary for the development and commercialization of Reverted Compounds; (B) [ * ] in BMS’ name; (C) [ * ] to the extent that [ * ];
(D) [ * ] Controlled by BMS; and (E) supplies of Product (including any intermediates, retained samples and reference standards) that in each case ((A) through (E)) are existing and in BMS’ Control and that [ * ] relate to such
Reverted Compounds. Any such transfer(s) shall be [ * ] of [ * ]. BMS and Exelixis shall promptly meet, over a [ * ] period, to negotiate in good faith the commercially reasonable terms of a license agreement to such Reverted Compounds (the
“Reverted Compounds License Agreement”), including: (1) the licenses described in Sections 11.5(a)(i) – (iv); (2) [ * ] under Section 11.5(a)(i), and [ * ] of other Reverted Compounds; (3) a
provision requiring BMS to use commercially reasonable efforts to maintain ([ * ]) and not to breach any agreements with Third Parties that provide a grant from such Third Party to BMS of rights that are Controlled by BMS and that are licensed to
Exelixis pursuant to the Reverted Compounds License Agreement; and (4) other customary terms and provisions, including terms and provisions relating to diligence, audit rights, and intellectual property maintenance and enforcement, in each case
substantially similar to the terms of this Agreement. 
 (b) BMS Internal Compound Research License. Notwithstanding the
licenses granted to Exelixis pursuant to Section 11(a), upon termination or expiration of this Agreement, BMS shall have a non-exclusive, worldwide, royalty-free license (without the right to sublicense except to third party contract
research providers and manufacturers), under the Exelixis Licensed Patents and Exelixis Licensed Know-How, to research, identify, derivatize, pre-clinically develop, make, have made and use Licensed Compounds that are BMS ROR Compounds solely for
research purposes. Notwithstanding anything to the contrary in this Agreement, the foregoing non-exclusive license grant shall not create (by any means, whether expressly, impliedly or by estoppel) any right or license under any other Patents,
Information or other intellectual property right that is Controlled by Exelixis. 
 11.6 Exception for Termination for [ *
]. The licenses granted to [ * ] under Sections [ * ] shall be [ * ] with respect to any given Product where [ * ] termination of Development and/or Commercialization of such Product was due to [ * ]. For purposes of this
Section 11.6, “[ * ]” means it is [ * ] or [ * ] or [ * ] that there is [ * ] for [ * ]: (i) [ * ], including [ * ]; or (ii) the [ * ] of [ * ] a Product [ * ] or [ * ], such as [ * ] or [ * ] a Product.
Notwithstanding anything to the contrary, 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 40 

 
this Section 11.6 shall not prevent [ * ] from using its licenses in Sections [ * ] to [ * ] by [ * ] that was [ * ]. [ * ] shall provide [ * ] with all [ * ] for such [ * ]
but shall not [ * ] to [ * ] any [ * ] relating to such [ * ]. 
 11.7 Interim Supply. In the event of any termination
pursuant to Section 11.2, or Section 11.3 (where BMS is the breaching Party), in each case [ * ], at Exelixis’ written request, BMS shall supply, or cause to be supplied, to Exelixis sufficient quantities of Product to
satisfy Exelixis’ requirements for Product for a period of up to [ * ] following the effective date of termination, as Exelixis may require until Exelixis can itself assume or transition to a Third Party such manufacturing responsibilities;
provided, however that Exelixis shall use Diligent Efforts to affect such assumption (or transition) as promptly as practicable. Such supply shall be [ * ] such Product(s) with respect to development supply, and shall be [ * ] such Product(s)
with respect to commercial supply. Any such supply will be made pursuant to a supply agreement between the Parties with typical provisions relating to quality, forecasting and ordering to forecast, force majeure and product liability and indemnity.
In the event that BMS has one or more agreements with Third Party manufacturers with respect to the manufacture of a Product, at Exelixis’ request, BMS shall use commercially reasonable efforts to transfer its rights and obligations under such
agreement(s) to Exelixis upon any such termination. 
  

	12.	REPRESENTATIONS AND WARRANTIES AND COVENANTS 

 12.1 Mutual Authority. Exelixis and BMS each represents and warrants to the other as of the Effective Date that: (a) it has the authority and right to enter into and perform this Agreement,
(b) this Agreement is a legal and valid obligation binding upon it and is enforceable in accordance with its terms, subject to applicable limitations on such enforcement based on bankruptcy laws and other debtors’ rights, and (c) its
execution, delivery and performance of this Agreement shall not conflict in any material fashion with the terms of any other agreement or instrument to which it is or becomes a party or by which it is or becomes bound, nor violate any law or
regulation of any court, governmental body or administrative or other agency having authority over it. 
 12.2 Rights in
Technology. 
 (a) During the term of this Agreement, each Party shall use commercially reasonable efforts to maintain
(but without an obligation to renew) and not to breach any agreements with Third Parties that provide a grant of rights from such Third Party to a Party that are Controlled by such Party and are licensed or become subject to a license from such
Party to the other Party under Article 7. Each Party agrees to provide promptly the other Party with notice of any such alleged breach or obligation to renew. As of the Effective Date, each Party is in compliance in all material respects with
any aforementioned agreements with Third Parties. 
 (b) Each Party represents and warrants that it: (i) has the
ability to grant the licenses contained in or required by this Agreement; and (ii) is not currently subject to any agreement with any Third Party or to any outstanding order, judgment or decree of any court or administrative agency that
restricts it in any way from granting to the other Party such licenses or the right to exercise its rights hereunder. 
 (c)
Each Party represents and warrants that: (i) it has not granted, and covenants 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 41 

 
that it shall not grant after the Effective Date and during the term of this Agreement, any right, license or interest in or to, or an option to acquire any of the foregoing with respect to, the
intellectual property rights licensed to the other Party hereunder (including the Exelixis Licensed Patents and the BMS Licensed Patents, as the case may be) that is in conflict with the rights (including the rights set forth in Article 7) or
licenses granted or to be granted (including any conditional license rights) to the other Party under this Agreement; and (ii) it has not granted any lien, security interest or other encumbrance (excluding any licenses) with respect to any of
the intellectual property rights licensed to the other Party hereunder that would prevent it from performing its obligations under this Agreement, or permitted such a lien, security interest or other encumbrance (excluding any permitted licenses) to
attach to the intellectual property rights licensed to the other Party hereunder. 
 12.3 Performance by Affiliates. The
Parties recognize that each may perform some or all of its obligations under this Agreement through Affiliates; provided, however, that each Party shall remain responsible and be guarantor of the performance by its Affiliates and shall cause
its Affiliates to comply with the provisions of this Agreement in connection with such performance. In particular, if any Affiliate of a Party participates under this Agreement with respect to Licensed Compounds: (a) the restrictions of this
Agreement which apply to the activities of a Party with respect to Licensed Compounds shall apply equally to the activities of such Affiliate; and (b) the Party affiliated with such Affiliate shall assure, and hereby guarantees, that any
intellectual property developed by such Affiliate shall be governed by the provisions of this Agreement (and subject to the licenses set forth in Article 7) as if such intellectual property had been developed by the Party. 

12.4 Third Party Rights. Each Party represents and warrants to the other Party that, to its Knowledge as of the Effective Date,
its performance of work as contemplated by this Agreement shall not infringe the valid patent, trade secret or other intellectual property rights of any Third Party. Each Party represents and warrants to the other Party that, to its Knowledge as of
the Effective Date, it will not violate a contractual or fiduciary obligation owed to any Third Party (including misappropriation of trade secrets) by performing its work as contemplated by this Agreement. 

12.5 Notice of Infringement or Misappropriation. Each Party represents and warrants to the other Party that, as of the Effective
Date, it has received no notice of infringement or misappropriation of any alleged rights asserted by any Third Party in relation to any technology that such Party intends, as of the Effective Date, to use in connection with the Agreement.

  

	13.	INDEMNIFICATION AND LIMITATION OF LIABILITY 

 13.1 Mutual Indemnification. Subject to Section 13.3, each Party hereby agrees to indemnify, defend and hold harmless the other Party, its Affiliates, and their respective directors,
employees and agents from and against any and all Third Party suits, claims, actions, demands, liabilities, expenses and/or losses, including reasonable legal expenses and reasonable attorneys’ fees (“Losses”) to the extent
such Losses result from any: (a) breach of warranty by the indemnifying Party contained in the Agreement; (b) breach of the Agreement or applicable law by such indemnifying Party; (c) negligence or willful misconduct of the
indemnifying Party, its Affiliates or (sub)licensees, or their respective directors, employees and agents in the performance of the Agreement; and/or (d) breach of a contractual or fiduciary obligation owed by it to a Third

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 42 

 
Party (including misappropriation of trade secrets). 
 13.2
Indemnification. 
 (a) Indemnification by BMS. Subject to Section 13.3, BMS hereby agrees to indemnify,
defend and hold harmless Exelixis and its directors, employees and agents from and against any and all Losses to the extent such Losses result from [ * ] or [ * ] by BMS or its Affiliates, agents or sublicensees, except to the extent such Losses
result from any: (a) breach of warranty by Exelixis contained in the Agreement; (b) breach of the Agreement or applicable law by Exelixis; (c) negligence or willful misconduct by Exelixis, its Affiliates or (sub)licensees, or their
respective directors, employees and agents in the performance of the Agreement; and/or (d) breach of a contractual or fiduciary obligation owed by Exelixis to a Third Party (including misappropriation of trade secrets). 

(b) Indemnification by Exelixis. Subject to Section 13.3, Exelixis hereby agrees to indemnify, defend and hold
harmless BMS and its directors, employees and agents from and against any and all Losses to the extent such Losses result from [ * ] or [ * ] by Exelixis or its Affiliates, agents or sublicensees, except to the extent such Losses result from any:
(a) breach of warranty by BMS contained in the Agreement; (b) breach of the Agreement or applicable law by BMS; (c) negligence or willful misconduct by BMS, its Affiliates or (sub)licensees, or their respective directors, employees
and agents in the performance of the Agreement; and/or (d) breach of a contractual or fiduciary obligation owed by BMS to a Third Party (including misappropriation of trade secrets). 

13.3 Conditions to Indemnification. As used herein, “Indemnitee” shall mean a party entitled to indemnification
under the terms of Sections 13.1 or 13.2. A condition precedent to each Indemnitee’s right to seek indemnification under such Sections 13.1 or 13.2 is that such Indemnitee shall: 

(a) inform the indemnifying Party under such applicable Section of a Loss as soon as reasonably practicable after it receives
notice of the Loss; 
 (b) if the indemnifying Party acknowledges that such Loss falls within the scope of its
indemnification obligations hereunder, permit the indemnifying Party to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Loss (including the right to settle the claim solely for monetary
consideration); provided, that the indemnifying Party shall seek the prior written consent (such consent not to be unreasonably withheld, delayed or conditioned) of any such Indemnitee as to any settlement which would materially diminish or
materially adversely affect the scope, exclusivity or duration of any Patents licensed under this Agreement, would require any payment by such Indemnitee, would require an admission of legal wrongdoing in any way on the part of an Indemnitee, or
would effect an amendment of this Agreement; and 
 (c) fully cooperate (including providing access to and copies of
pertinent records and making available for testimony relevant individuals subject to its control) as reasonably requested by, and at the expense of, the indemnifying Party in the defense of the Loss. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 43 

 Provided that an Indemnitee has complied with all of the conditions described in subsections 13.3(a)
– (c), as applicable, the indemnifying Party shall provide attorneys reasonably acceptable to the Indemnitee to defend against any such Loss. Subject to the foregoing, an Indemnitee may participate in any proceedings involving such Loss
using attorneys of the Indemnitee’s choice and at the Indemnitee’s expense. In no event may an Indemnitee settle or compromise any Loss for which the Indemnitee intends to seek indemnification from the indemnifying Party hereunder without
the prior written consent of the indemnifying Party (such consent not to be unreasonably withheld, delayed or conditioned), or the indemnification provided under such Section 13.1 or 13.2 as to such Loss shall be null and void.

 13.4 Limitation of Liability. EXCEPT FOR AMOUNTS PAYABLE TO THIRD PARTIES BY A PARTY FOR WHICH IT SEEKS REIMBURSEMENT
OR INDEMNIFICATION PROTECTION FROM THE OTHER PARTY PURSUANT TO SECTIONS 13.1 AND 13.2, AND EXCEPT FOR BREACH OF SECTION 10.1 HEREOF, IN NO EVENT SHALL EITHER PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO
THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THE AGREEMENT,
UNLESS SUCH DAMAGES ARE DUE TO THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF THE LIABLE PARTY (INCLUDING GROSS NEGLIGENCE OR WILLFUL BREACH WITH RESPECT TO A PARTY’S REPRESENTATIONS AND WARRANTIES IN ARTICLE 12). FOR CLARITY, THE AMOUNT
OF THE UPFRONT PAYMENTS DESCRIBED IN SECTION 8.1 MAY SERVE AS A MEASURE OF A REMEDY IN THE EVENT OF A BREACH WITH RESPECT TO EXELIXIS’ REPRESENTATIONS AND WARRANTIES IN ARTICLE 12. 

13.5 Agreement Disclaimer. EXCEPT AS PROVIDED IN ARTICLE 12 ABOVE, BMS EXPRESSLY DISCLAIMS ANY AND ALL OTHER WARRANTIES OF
ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES WITH RESPECT TO ANY COMPOUNDS, MATERIALS OR INFORMATION
(AND ANY PATENT RIGHTS OBTAINED THEREON) IDENTIFIED, MADE OR GENERATED BY BMS AS PART OF THE COLLABORATION OR OTHERWISE MADE AVAILABLE TO EXELIXIS PURSUANT TO THE TERMS OF THE AGREEMENT. EXCEPT AS PROVIDED IN ARTICLE 12 ABOVE, EXELIXIS
EXPRESSLY DISCLAIMS ANY AND ALL OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES WITH
RESPECT TO ANY COMPOUNDS, MATERIALS OR INFORMATION (AND ANY PATENT RIGHTS OBTAINED THEREON) IDENTIFIED, MADE OR GENERATED BY EXELIXIS AS PART OF THE COLLABORATION OR OTHERWISE MADE AVAILABLE TO BMS PURSUANT TO THE TERMS OF THE AGREEMENT. 

 

	14.	MISCELLANEOUS 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 44 

 14.1 Dispute Resolution. Unless otherwise set forth in this Agreement and excluding
in particular any dispute described in Section 14.3(a), Section 14.3(b), Section [ * ] (which will be handled exclusively in accordance with Section [ * ]), Section [ * ] (which will be handled exclusively in
accordance with Section [ * ])and any dispute handled pursuant to Sections [ * ], in the event of any dispute, controversy or claim arising out of, relating to or in connection with any provision of the Agreement, the Parties shall try
to settle their differences amicably between themselves first, by referring the disputed matter to the Party’s respective Executive Officers. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to
the other Party, and, within [ * ] after such notice, such Executive Officers shall meet for attempted resolution by good faith negotiations. If such Executive Officers are unable to resolve such dispute within [ * ] of their first meeting for such
negotiations, either Party may seek to have such dispute resolved in any U.S. federal or state court of competent jurisdiction and appropriate venue, provided, that if such suit includes a Third Party claimant or defendant, and jurisdiction
and venue with respect to such Third Party appropriately resides outside the U.S., then in any other jurisdiction or venue permitted by applicable law. 
 14.2 Governing Law. Resolution of all disputes, controversies or claims arising out of, relating to or in connection with the Agreement or the performance, enforcement, breach or termination of the
Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of Delaware, without regard to conflicts of law rules. 
 14.3 Patents and Trademarks; Equitable Relief. 
 (a) General Patent and
Trademark Disputes. Except as set forth in Sections 14.3(c) and (d), any dispute, controversy or claim arising out of, relating to or in connection with: (i) the scope, validity, enforceability or infringement of any Patent
rights covering the research, development, manufacture, use or sale of any Product; or (ii) any trademark rights related to any Product, shall in each case be submitted to a court of competent jurisdiction in the territory in which such Patent
or trademark rights were granted or arose. 
 (b) Equitable Relief. Any dispute, controversy or claim arising out of,
relating to or in connection with the need to seek preliminary or injunctive measures or other equitable relief (e.g., in the event of a potential or actual breach of the confidentiality and non-use provisions in Article 10) need not be
resolved through the procedure described in Section 14.1 but may be immediately brought in a court of competent jurisdiction. 
 (c) Disputes Related to Subsection [ * ]. Any dispute that concerns whether [ * ] a [ * ] (other than [ * ] of a [ * ]) would [ * ] and that is not resolved by discussion pursuant to Section [ *
] shall be finally resolved through binding arbitration by JAMS (formerly, the Judicial Arbitration and Mediation Service) (“JAMS”), in accordance with its Streamlined Arbitration Rules and Procedures in effect at the time the
dispute arises, and applying the substantive law specified in Section 14.2. Either Party may initiate arbitration under this Section 14.3(c) by written notice to the other Party of its intention to arbitrate, and such notice
shall specify in reasonable detail the nature of the dispute. Promptly following receipt of such notice, the Parties shall meet and discuss in good faith and agree on an arbitrator to resolve the issue, which arbitrator shall be neutral and
independent of both Parties, shall have significant experience and expertise in [ * ] pharmaceutical products, and shall have some experience in mediating or arbitrating issues relating to such [ * ]. If

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 45 

 
the Parties cannot agree on such arbitrator within [ * ] of request by a Party for arbitration, then such arbitrator shall be appointed by JAMS, which arbitrator must meet the foregoing criteria.
For each arbitration: (i) each Party shall submit to the arbitrator its memorandum (the “Support Memorandum”) in support of its position in the dispute; and (ii) the arbitrator shall determine which Party’s position
is correct. If the arbitrator’s determination is in [ * ] favor, then [ * ] would not [ * ] under Section [ * ] for such [ * ]; however, if the arbitrator’s determination is in [ * ] favor, then [ * ] would [ * ] under Section [
* ] for such [ * ]. The decision of the arbitrator shall be final and judgment upon such decision may be entered in any competent court or application may be made to any competent court for judicial acceptance of such decision and order of
enforcement. The arbitration proceedings shall be conducted at such location as shall be determined by the arbitrator. The Parties agree that they shall share equally the cost of the arbitration filing and hearing fees, and the cost of the
arbitrator. Each Party shall bear its own attorneys’ fees and associated costs and expenses. 
 (d) Disputes Related to
Subsection [ * ]. If [ * ] and the [ * ] that [ * ] pursuant to Subsection [ * ] do not agree upon [ * ] that reasonably [ * ] within [ * ] after the [ * ] such [ * ], then either party may, by written notification to the other party,
submit the matter to binding “baseball” arbitration to determine the terms of such [ * ], as follows. Promptly following receipt of such notice, the parties shall meet and discuss in good faith and agree on an arbitrator to resolve the
issue, which arbitrator shall be neutral and independent of both parties, shall have significant experience and expertise in [ * ] pharmaceutical products and in [ * ] as part of collaboration agreements, and shall have some experience in mediating
or arbitrating issues relating to such [ * ]. If the parties cannot agree on such arbitrator within [ * ] of request by a party for arbitration, then such arbitrator shall be appointed by JAMS, which arbitrator must meet the foregoing criteria.
Within [ * ] after an arbitrator is selected (or appointed, as the case may be), each party will deliver to both the arbitrator and the other party a detailed written proposal setting forth its proposed terms for the [ * ] containing the reasonable
[ * ] (the “Proposed Terms” of the party) and a Support Memorandum, not exceeding [ * ] in length. The parties will also provide the arbitrator a copy of this Agreement, as may be amended at such time. Within [ * ] after receipt of
the other party’s Proposed Terms and Support Memorandum, each party may submit to the arbitrator (with a copy to the other party) a response to the other party’s Support Memorandum, such response not exceeding [ * ] in length. Neither
party may have any other communications (either written or oral) with the arbitrator other than for the sole purpose of engaging the arbitrator or as expressly permitted in this Section 14.3(d); provided that, the arbitrator may convene
a hearing if the arbitrator so chooses to ask questions of the parties and hear oral argument and discussion regarding each party’s Proposed Terms. Within [ * ] after the arbitrator’s appointment, the arbitrator will select one of the two
(2) Proposed Terms (without modification) provided by the parties that he or she believes is most consistent with the intention underlying and agreed principles set forth in this Agreement and most accurately reflects industry norms for a
transaction of this type. The decision of the arbitrator shall be final, binding, and unappealable and the parties shall promptly [ * ] having the terms set forth in the Proposed Terms selected by the arbitrator. For clarity, the arbitrator must
select as the only method to determine the [ * ] one of the two (2) sets of Proposed Terms, and may not combine elements of both Proposed Terms or take any other action. Except as expressly stated in this Section 14.3(d), such
arbitration shall be conducted in accordance with JAMS’ Streamlined Arbitration Rules and Procedures then in effect. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 46 

 14.4 Entire Agreement; Amendments. This Agreement, the LXR Collaboration Agreement,
the license agreement (for the discovery, development and commercialization of compounds that agonize the target known as TGR5) that is between Exelixis and BMS and that is dated as of the Effective Date (the “TGR5 License
Agreement”), and the letter agreement that is dated as of the Effective Date and that describes Exelixis’ creation of a licensing Affiliate (the “Letter Agreement”), set forth the complete, final and exclusive
agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and understandings between the Parties. There are no
covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement, the LXR Collaboration Agreement, the TGR5 License Agreement and
the Letter Agreement. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 

14.5 Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information
from the U.S. or other countries which may be imposed upon or related to Exelixis or BMS from time to time. Each Party agrees that it shall not export, directly or indirectly, any technical information acquired from the other Party under this
Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate
agency or other governmental entity. 
 14.6 Bankruptcy. 

(a) All rights and licenses granted under or pursuant to this Agreement, including amendments hereto, by each Party to the other
Party are, for all purposes of Section 365(n) of Title 11 of the U.S. Code (“Title 11”), licenses of rights to intellectual property as defined in Title 11. Each Party agrees during the term of this Agreement to create and
maintain current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all such intellectual property. If a case is commenced by or against either Party (the “Bankrupt
Party”) under Title 11, then, unless and until this Agreement is rejected as provided in Title 11, the Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 Trustee) shall, at
the election of the Bankrupt Party made within sixty (60) days after the commencement of the case (or, if no such election is made, immediately upon the request of the non-Bankrupt Party) either (i) perform all of the obligations provided
in this Agreement to be performed by the Bankrupt Party including, where applicable, providing to the non-Bankrupt Party portions of such intellectual property (including embodiments thereof) held by the Bankrupt Party and such successors and
assigns or otherwise available to them or (ii) provide to the non-Bankrupt Party all such intellectual property (including all embodiments thereof) held by the Bankrupt Party and such successors and assigns or otherwise available to them.

 (b) If a Title 11 case is commenced by or against the Bankrupt Party and this Agreement is rejected as provided in
Title 11 and the non-Bankrupt Party elects to retain its rights hereunder as provided in Title 11, then the Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 Trustee) shall provide
to the non-Bankrupt Party all such intellectual property (including all embodiments thereof) held by the 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 47 

 
Bankrupt Party and such successors and assigns or otherwise available to them immediately upon the non-Bankrupt Party’s written request therefor. Whenever the Bankrupt Party or any of its
successors or assigns provides to the non-Bankrupt Party any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section 14.6, the non-Bankrupt Party shall have the right to perform the
obligations of the Bankrupt Party hereunder with respect to such intellectual property, but neither such provision nor such performance by the non-Bankrupt Party shall release the Bankrupt Party from any such obligation or liability for failing to
perform it. 
 (c) All rights, powers and remedies of the non-Bankrupt Party provided herein are in addition to and not
in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including Title 11) in the event of the commencement of a Title 11 case by or against the Bankrupt Party. The non-Bankrupt Party, in
addition to the rights, power and remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such remedies as may now or hereafter exist at law or in equity (including under Title 11)
in such event. The Parties agree that they intend the foregoing non-Bankrupt Party rights to extend to the maximum extent permitted by law and any provisions of applicable contracts with Third Parties, including for purposes of Title 11,
(i) the right of access to any intellectual property (including all embodiments thereof) of the Bankrupt Party or any Third Party with whom the Bankrupt Party contracts to perform an obligation of the Bankrupt Party under this Agreement, and,
in the case of the Third Party, which is necessary for the development, registration and manufacture of Products and (ii) the right to contract directly with any Third Party described in (i) in this sentence to complete the contracted
work. Any intellectual property provided pursuant to the provisions of this Section 14.6 shall be subject to the licenses set forth elsewhere in this Agreement and the payment obligations of this Agreement, which shall be deemed to be
royalties for purposes of Title 11. 
 14.7 Force Majeure. Each Party shall be excused from the performance of its
obligations under this Agreement to the extent that such performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as
the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement, “force majeure” shall include conditions beyond the control of the
Parties, including an act of God, acts of terrorism, voluntary or involuntary compliance with any regulation, law or order of any government, war, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common
carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. The payment of invoices due and owing hereunder shall in no event be delayed by the payer because of a force majeure affecting the payer.

 14.8 Notices. Any notices given under this Agreement shall be in writing, addressed to the Parties at the following
addresses, and delivered by person, by facsimile (with receipt confirmation), or by FedEx or other reputable courier service. Any such notice shall be deemed to have been given: (a) as of the day of personal delivery; (b) one (1) day
after the date sent by facsimile service; or (c) on the day of successful delivery to the other Party confirmed by the courier service. Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below.

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 48 

			
	For Exelixis:	  	Exelixis, Inc.
		  	170 Harbor Way
		  	P.O. Box 511
		  	So. San Francisco, CA 94083-0511
		  	Attention: EVP, General Counsel
		
	With a copy to:	  	Cooley LLP
		  	Five Palo Alto Square
		  	3000 El Camino Real
		  	Palo Alto, CA 94306
		  	Attention: Marya A. Postner, Esq.
		
	For BMS:	  	Bristol-Myers Squibb Company
		  	P.O. Box 4000
		  	Route 206 and Province Line Road
		  	Princeton, NJ 08543-4000
		  	Attention: Senior Vice President, Strategy, Alliances and Transactions
		  	Phone: 609-252-5333
		  	Fax: 609-252-7212
		
	With a copy to:	  	Bristol-Myers Squibb Company
		  	P.O. Box 4000
		  	Route 206 and Province Line Road
		  	Princeton, NJ 08543-4000
		  	Attention: Vice President and Senior Counsel, Corporate and Business Development
		  	Phone: 609-252-5328
		  	Fax: 609-252-4232

 Furthermore, a copy of any notices
required or given under Article 7 of this Agreement shall also be addressed to the [ * ] of [ * ] at the address set forth in Section 7.8(f). 
 14.9 Maintenance of Records Required by Law or Regulation. Each Party shall keep and maintain all records required by law or regulation with respect to Products and shall make copies of such
records available to the other Party upon request. 
 14.10 Assignment. Neither Party may assign or transfer this
Agreement or any rights or obligations hereunder without the prior written consent of the other (such consent not to be unreasonably withheld, delayed or conditioned), except a Party may make such an assignment without the other Party’s consent
to an Affiliate or to a Third Party successor to all or substantially all of the business of such Party to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other transaction; provided that any such permitted
successor or assignee of rights and/or obligations hereunder is obligated, by reason of operation of law or pursuant to a written agreement with the other Party, to assume performance of this Agreement or such rights and/or obligations; and
provided, further, that if assigned to an Affiliate, the assigning Party shall remain jointly and severally responsible for the performance of this Agreement by such Affiliate. Any 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 49 

 
permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 14.10
shall be null and void and of no legal effect. 
 14.11 Electronic Data Interchange. If both Parties elect to facilitate
business activities hereunder by electronically sending and receiving data in agreed formats (also referred to as Electronic Data Interchange or “EDI”) in substitution for conventional paper-based documents, the terms and conditions
of this Agreement shall apply to such EDI activities. 
 14.12 Non-Solicitation of Employees. [ * ], each Party agrees
that neither it nor any of its divisions, operating groups or Affiliates shall recruit, solicit or induce any employee of the other Party directly involved in the activities conducted pursuant to this Agreement to terminate his or her employment
with such other Party and become employed by or consult for such Party, whether or not such employee is a full-time employee of such other Party, and whether or not such employment is pursuant to a written agreement or is at-will. For purposes of
the foregoing, “recruit”, “solicit” or “induce” shall not be deemed to mean: (a) circumstances where an employee of a Party initiates contact with the other Party or any of its Affiliates with
regard to possible employment; or (b) general solicitations of employment not specifically targeted at employees of a Party or any of its Affiliates, including responses to general advertisements. 

14.13 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other
acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 14.14
Severability. If any of the provisions of this Agreement are held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and
shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when
entering this Agreement may be realized. 
 14.15 No Waiver. Any delay in enforcing a Party’s rights under this
Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as
to a particular matter for a particular period of time. 
 14.16 Construction of this Agreement. Except where the context
otherwise requires, wherever used, the use of any gender shall be applicable to all genders, and the word “or” are used in the inclusive sense. When used in this Agreement, “including” means “including
without limitation”. References to either Party include the successors and permitted assigns of that Party. The headings of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or
intent of this Agreement or the intent of any provision contained in this Agreement. The Parties have each consulted counsel of their choice regarding this Agreement, and, accordingly, no provisions of this Agreement shall be construed against
either Party on the basis that the Party drafted this Agreement or any provision thereof. If the terms of this Agreement conflict with the terms of any Exhibit, then the terms of this Agreement shall govern. The official text of this Agreement and
any Exhibits hereto, any notice given or accounts or 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 50 

 
statements required by this Agreement, and any dispute proceeding related to or arising hereunder, shall be in English. In the event of any dispute concerning the construction or meaning of this
Agreement, reference shall be made only to this Agreement as written in English and not to any other translation into any other language. 
 14.17 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which shall constitute together the same document.
Counterparts may be signed and delivered by facsimile, or electronically in PDF format, each of which shall be binding when sent. 
 Signature page follows. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 51 

 IN WITNESS WHEREOF, the
Parties have executed this Agreement in duplicate originals by their proper officers. Further, the Parties agree that the signature dates below reflect the actual date of signatures by the Parties and may not be the effective date of this Agreement.

  

									
	BRISTOL-MYERS SQUIBB COMPANY	  		  	EXELIXIS, INC.
					
	By:	  	             /s/ Jeremy
Levin
	  		  	By:	  	             /s/ Michael
Morrissey

									
					
	Title:	  	             Senior Vice
President
	  		  	Title:	  	         CEO

					
	Date:	  	             10/08/2010
	  		  	Date:	  	         10/08/2010

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 52 

 Exhibit 4.2 
 Form of Transfer Addendum 
 This Transfer Addendum No.
     (the “Transfer Addendum”) to the license agreement between Bristol-Myers Squibb Company and Exelixis, Inc., effective as of
            , 2010 (the “License Agreement”), is made as of
                     {Note: Please insert date} (the “Addendum Effective Date”), by and between: 

Transferring Party: Exelixis, Inc. 
 And 
 Receiving Party: Bristol-Myers Squibb Company 

for the transfer of: 
 (1) Information:

 {Note: Please identify any Information other than the Materials that would be transferred, e.g., assay protocols, or else add
“N/A” if not applicable.} 
 (2) Materials: 
 (i) the following biological materials: 
 {Note: Please identify any cell-lines, reagents,
genes, vectors and constructs that would be transferred, or else add “N/A” if not applicable.} 
 (ii) the following {Licensed
Compounds} known as: 
 {Note: Please insert identifier of the applicable compounds, or else add “N/A” if not applicable.}

 Terms and Special Terms 

The Parties agree that the transfer of the above defined Information and Materials pursuant to this Transfer Addendum shall be covered and submitted to
the terms and conditions of the License Agreement. Any special terms and conditions identified on Appendix A, attached hereto and incorporated herein, shall also apply to the transfer of the Materials under this Transfer Addendum. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

 IN WITNESS WHEREOF, this Transfer Addendum is entered into as of the Addendum Effective Date, and it is
accepted and agreed to by the Parties’ authorized representatives. The date that this Transfer Addendum is signed shall not be construed to imply that the document was made effective on that date. 

 

									
	  
	  		  	  

	Name: {Note: insert name of AM}	  		  	Name: {Note: insert name of AM}
	For Exelixis	  		  	For BMS
					
	Title:	 	       Alliance Manager
	  		  	Title:	 	       Alliance Manager

					
	Date:	 	  
	  		  	Date:	 	  

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2 

 Appendix A to Transfer Addendum 

Special Terms 
 The
following special terms and conditions apply to the transfer of the Materials under this Transfer Addendum. 
 {Note: Please identify any
special terms and conditions, or else add “N/A” if not applicable.} 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 3 

 Exhibit 10.5 
 Press Release 
 Contact: 

Charles Butler 

Vice President 

Corporate Communications 
 & Investor Relations 
 Exelixis, Inc. 

(650) 837-7277 

cbutler@exelixis.com 
 DeDe Sheel 
 Associate Director, 

Investor Relations 
 Exelixis, Inc. 
 (650) 837-8231 

dsheel@exelixis.com 
 EXELIXIS LICENSES PROGRAMS TO BRISTOL-MYERS SQUIBB COMPANY 
 -Exelixis
to receive initial payment of $60 million- 
 SOUTH SAN FRANCISCO, Calif., October XX, 2010 — Exelixis, Inc. (NASDAQ: EXEL)
announced today that it has entered into two new collaboration agreements with Bristol-Myers Squibb Company (NYSE:BMY). Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist
program including backups. Under the second agreement, the companies will collaborate to discover, optimize, and characterize small-molecule ROR antagonists. The companies have also made minor amendments to their XL281 and liver X receptor (LXR)
agreements. Finally, under the companies’ cancer collaboration agreement Exelixis has opted to exercise its right to opt out of further co-development of XL139 and will receive an accelerated milestone payment. 

Under the terms of the new agreements, Bristol-Myers Squibb will make a combined initial payment of $60 million to Exelixis. Exelixis will be eligible
for potential development and approval milestone payments of up to $250 million on TGR5 and $255 million on the ROR antagonists. Exelixis will also be eligible for combined sales performance milestones, and royalties on net sales of products from
each of the TGR5 and ROR programs. Bristol-Myers Squibb will receive an exclusive worldwide license to develop and commercialize small molecule TGR5 agonists and ROR antagonists. Under the TGR5 agreement, Bristol-Myers Squibb will have sole
responsibility for research, development, manufacturing, and commercialization. Under the ROR agreement, Bristol-Myers Squibb and Exelixis will collaborate on ROR antagonist programs up to a pre-clinical transition point and then Bristol-Myers
Squibb will have sole responsibility for the further research, development, manufacture, and commercialization. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

 Exelixis is granting rights to the ROR program in exchange for Bristol-Myers Squibb waiving rights to
receive a third Investigational New Drug (IND) candidate as agreed to under a collaboration signed in 2006 between the two companies in the area of oncology. 
 After Exelixis opts-out of further co-development of XL139, Bristol-Myers Squibb will receive an exclusive worldwide license to develop and commercialize, and will have sole responsibility for the further
development, manufacture, and commercialization of the compound. 
 “We continue our strong relationship with Bristol-Myers Squibb and are
excited for these collaborations to maximize the potential of these novel programs and bring benefits to patients with serious diseases,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “These
transactions leverage our discovery expertise with the development expertise of Bristol-Myers Squibb in inflammation and metabolic diseases, and provide important additional resources for us to continue our focus on our clinical stage development
pipeline.” 
 TGR5 is a G-protein coupled bile acid receptor (GPCR) which is highly expressed in the gall bladder and intestine. Through
TGR5, bile acids promote the secretion of glucogen-like peptide-1 (GLP-1), a hormone that affects multiple metabolic parameters including increased insulin secretion from the pancreas and lowering of blood glucose. Stimulating GLP-1 secretion by
activation of TGR5 has the potential to be complementary to the use of dipeptidyl peptidase-4 (DPP-IV) inhibitors for the treatment of diabetes. 
 ROR is a member of the nuclear hormone receptor family that is expressed in multiple cell types including T-cells. ROR plays a prominent role in the development and activity of the TH17 subset of T-cells,
which secrete IL-17 and are associated with a variety of inflammatory disorders. Small molecule antagonists of ROR inhibit production of these pro-inflammatory cytokines and have broad potential as novel anti-inflammatory compounds. 

The TGR5 license agreement and the amendment to the 2007 cancer collaboration agreement are subject to antitrust clearance under the Hart-Scott-Rodino
Antitrust Improvements Act and other customary regulatory approvals.  
 About Exelixis 

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the
treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial
potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established
strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and
Daiichi-Sankyo. For more information, please visit the company’s web site at http://www.exelixis.com. 
 Exelixis and the Exelixis
logo are registered U.S. trademarks. 
 {Insert Forward-Looking Statements} 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2Letter agreement

 Exhibit 4.2 
 United Air Lines, Inc. 
 1200 Algonquin Road 

Elk Grove Village, IL 60007 
 February 9, 2007 
 JPMorgan Chase Bank, N.A. 

270 Park Avenue 
 New York, New York 10017

 Attention: Matthew Massie 
 Citicorp
USA, Inc. 
 388 Greenwich Street 
 19th
Floor 
 New York, New York 10013 

Attention: James J. McCarthy 
  

	 	Re:	Amended and Restated Revolving Credit, Term 

 Loan and Guaranty Agreement 
 Ladies and Gentlemen: 

We refer to that certain Amended and Restated Revolving Credit, Term Loan and Guaranty Agreement dated as of February 2, 2007 among JPMorgan Chase
Bank, N.A., as Co-Administrative Agent, Co-Collateral Agent and Paying Agent, Citicorp USA, Inc., as Co-Administrative Agent and Co-Collateral Agent, J.P. Morgan Securities Inc., as Joint Lead Arranger and Joint Bookrunner, Citigroup Global Markets,
Inc., as Joint Lead Arranger and Joint Bookrunner, Credit Suisse Securities (USA) LLC, as Syndication Agent and the Lenders named therein (the “Credit Agreement”). All terms used herein that are defined in the Credit Agreement shall
have the same meanings herein. 
 Section 2.06(b) of the Credit Agreement provides that each Eurodollar Loan that is a Tranche A Loan shall
bear interest at a rate per annum that is equal to the Adjusted LIBO Rate for relevant Interest Periods plus a margin of 2.00%. Section 2.20 of the Credit Agreement provides that the Borrower shall pay Letter of Credit Fees at the rate of two
and one-quarter percent (2.25%) per annum on the daily average L/C Exposure. 
 It was the understanding of the Borrower and the Agents
that Letter of Credit Fees would be calculated at a rate per annum that is equal to the margin in excess of the Adjusted LIBO Rate for Tranche A Loans. When the Tranche A margin in Section 2.06(b) of the

 
Credit Agreement was reduced from 2.25% to 2.00% (a change that was implemented very shortly before closing), the corresponding change that should have been made in Section 2.20, to reduce
Letter of Credit Fees from 2.25% to 2.00%, was inadvertently not made. 
 Section 10.08(d) of the Credit Agreement permits the Agents and
the Borrower to amend Loan Document provisions to correct what the Agents and the Borrower jointly identify as an “obvious error” or an “error or omission of a technical or immaterial nature”. The Borrower hereby requests the
Agents to (i) acknowledge that the higher Fees in Section 2.20, when compared to the rate in Section 2.06(b), is an obvious error, (ii) agree that clause (a) of Section 2.20 of the Credit Agreement is hereby amended as
of February 2, 2007 by deleting the words “two and one-quarter percent (2.25%)” appearing therein and inserting in lieu thereof the words “two percent (2.00%)” and (iii) agree that present page 53 of the Credit
Agreement will be replaced with the attached copy of page 53 (the only change on which is the reduction of the L/C Fee as described in the preceding clause (ii)). 
 The Borrower understands that the above amendment shall become effective without any further action or consent of any other party to any Loan Document if the same is not objected to in writing by the
Required Lenders within five (5) Business Days’ notice thereof and that the Agents will post this letter and the changed page referred to above to the public and private Intralinks site in use for the Credit Agreement. 

If you are in agreement with the foregoing, kindly sign and return a copy of this letter to the Borrower. 

This letter agreement may be executed in one or more counterparts and by different parties hereto on different counterparts, each of which shall
constitute an original but all of which when taken together shall constitute but one instrument, and shall become effective. Delivery of an executed signature page to this Agreement by telecopy or electronic .pdf copy shall be effective as delivery
of a manually executed counterpart hereof. 
 Except as expressly set forth herein, nothing in this letter agreement shall be deemed to be an
amendment or modification of any other term or provision of the Credit Agreement or any of the other Loan Documents. 
  

					
	Very truly yours,
	
	UNITED AIR LINES, INC.
		
	By:	 	 /s/ Frederic F. Brace

		 	Name:	 	Frederic F. Brace
		 	Title:	 	Executive Vice President and Chief Financial Officer

 ACKNOWLEDGED AND AGREED TO: 

 

					
	JPMORGAN CHASE BANK, N.A.
		
	By:	 	 /s/ Matthew H. Massie

		 	Name:	 	Matthew H. Massie
		 	Title:	 	Managing Director
	
	CITICORP USA, INC.
		
	By:	 	 /s/ James J. McCarthy

		 	Name:	 	James J. McCarthy
		 	Title:	 	Managing Director & Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]